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ABSTRACT 
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder that 
creates significant healthcare needs and greatly impacts families. As interventions improving life 
quality and expectancy have become available and as care recommendations have been 
established, it has become increasingly important to understand what services families are 
utilizing and their perceptions of this care. This study describes data from the US National 
Initiative for Families with Duchenne (NIFD) questionnaire, which was designed in part to 
explore these aspects of families’ experiences. Differences between sub-populations in the 
dataset and associations between survey variables were analyzed. NIFD data were compared to 
data from a more recent patient registry, DuchenneConnect (DC), which also assesses healthcare 
utilization in individuals with DMD. 
Child’s health status and medical care variables were examined from 191 NIFD surveys 
completed by family members of children with DMD. While many families were receiving 
multidisciplinary care, timing of first visits and the need for certain providers were shown as 
areas where families could use more education. Socioeconomic differences between NIFD sub-
populations revealed possible explanations for differences in care. Factors associated with pain 
frequency and overall life satisfaction in individuals with DMD emphasize the need for 
multidisciplinary care and provide areas where healthcare providers can assist families. 
Robin E. Grubs, Ph.D., CGC 
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Comparison of NIFD and DC data revealed a wider phenotypic spectrum in the latter 
group. DC registrants reported less problems with certain medical expenses and higher use of 
therapies. These differences point to the need to assess a large population to develop an accurate 
picture of DMD and hopefully indicate that awareness and access to important services and 
interventions has improved over time. 
DMD is the most common fatal genetic disorder affecting children across all ethnic 
backgrounds. This high, pan-ethnic incidence as well the significant impact of the disease on 
individuals with DMD and their families make this a condition of public health concern. 
Understanding service utilization as well as families’ perceptions of it will help in addressing 
potential gaps and barriers experienced in caring for individuals with DMD and will thus inform 
public health policies to help these families. 
v 
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 1.0  INTRODUCTION 
Duchenne muscular dystrophy (DMD) is a neuromuscular disorder with X-linked inheritance. It 
is one of the most common genetic conditions with an incidence of about 1 in 3,300 to 5,300 
male births. Mutations in the gene encoding the dystrophin protein lead to progressive loss of 
muscle strength in major body systems, ultimately causing loss of the ability to walk and perform 
daily activities and eventually death.  
 The impact of this debilitating condition on those affected by it and their families is 
significant. While a cure has not yet been identified, the development of new treatments and 
interventions over time has greatly enhanced the quality of life and life expectancy of individuals 
with DMD. These developments have come about with the cooperation of multiple groups 
including researchers, physicians and parents of children with DMD. The Cooperative 
International Neuromuscular Research Group (CINRG) has been one of the key players in DMD 
clinical research with its network of US and international study sites. 
 As the natural history of DMD and the effects of newer interventions have been studied, a 
move towards establishing care guidelines has developed over the last decade. The sum of these 
efforts has resulted in DMD care recommendations in 2010. These documents outline key areas 
of complex multidisciplinary care, with the aim of standardizing and diminishing disparities in 
the care of those with DMD. As these guidelines have evolved it has been less clear what kind of 
care families are actually receiving as well as their perceptions of this care and its impacts. Thus, 
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 several efforts have been launched to better understand these aspects of families’ experiences. 
The National Initiative for Families with Duchenne (NIFD) survey was developed in partnership 
with the Center for Disease Control and Prevention (CDC) to assess the experiences and needs 
for US families with DMD. Data were obtained between 2006 and 2009. This present study 
analyzes data from the NIFD survey to explore healthcare utilization as well as families’ 
perceptions of it and how it may impact families. The relationships between demographic and 
other variables were analyzed to identify differences in access and use of various services and 
interventions. Data from DuchenneConnect (DC), a US patient registry with data from 2007 to 
2013, were compared to NIFD data to assess similarities and differences with another DMD 
patient population. 
Understanding what services families are utilizing and identifying potential barriers to 
them is important in establishing a global standard of care for those with DMD. This knowledge 
will complement current efforts to develop DMD centers of excellence and initiatives to ensure 
the DMD care recommendations are actively integrated into the care of all individuals with 
DMD.  
 2 
 2.0  HYPOTHESIS AND SPECIFIC AIMS  
2.1 HYPOTHESIS 
As there is a move for standardization of care for DMD, families may not be receiving care 
consistent with recommendations due to differences in socioeconomic factors, perceived 
importance of care and availability of services. 
2.2 SPECIFIC AIMS 
Aim 1: To characterize demographic, health status, healthcare utilization and perceptions of care 
data from the NIFD survey. 
 
Aim 2: To compare demographic and healthcare differences between NIFD sub-populations and 
explore associations between survey variables including those assessing impact and care 
received. 
 
Aim 3: To compare NIFD data to data from DuchenneConnect, a web-based patient survey, to 
assess similarities and differences in healthcare utilization between the two populations. 
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 3.0  BACKGROUND AND SIGNIFICANCE 
3.1 DUCHENNE MUSCULAR DYSTROPHY 
DMD is a progressive, neuromuscular disease predominantly affecting males with estimates of 
incidence between 1 in 3,300 to 1 in 5,300 of male live births (Engel and Banker 1986; Emery 
1991; Bradley and Parsons 1998; Dooley et al. 2010). A population-based study from four US 
states estimated the prevalence of Duchenne/Becker muscular dystrophy (DBMD) to be 1.3 to 
1.8 per 10,000 males age 5 to 24 years (Romitti et al. 2009). DMD is the most common fatal 
genetic condition in children (Hinton et al. 2001). 
 DMD is an X-linked condition associated with deletions, point mutations, and 
duplications in the dystrophin (DMD) gene. It is estimated that two thirds of cases inherit a 
dystrophin lesion from their mother while the remaining third possess a spontaneous mutation, 
owing to a high mutation rate in the DMD gene (Koenig et al. 1987; Bradley and Parsons 1998; 
Webb 2005). The dystrophin protein encoded by DMD serves as a stabilizing force within 
muscle structure (Gorospe and Hoffman 1992; Matsumura et al. 1993). Without functional 
dystrophin protein, the process of muscle degradation and regeneration is impaired leading to 
muscle wasting and replacement of muscle tissues with fat and connective tissue.  
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  While one of the first signs of DMD, elevated creatine kinase levels, can be detected in 
the newborn period, physical manifestations of the disease are not usually recognized until the 
first to third year of life with diagnosis typically occurring by four to five years of age (Appleton 
and Nicolaides 1995; Bushby et al. 1999; Zalaudek et al. 1999; Parsons et al. 2004; Ciafaloni et 
al. 2009). These initial physical symptoms include developmental delays (locomotor, speech and 
cognitive in some) followed by abnormal gait, enlarged calves, toe-walking, frequent falls and 
clumsiness, muscle weakness and difficulty running, jumping, and climbing stairs (Firth et al. 
1983; Bushby et al. 1999; Parsons et al. 2004; Ciafaloni et al. 2009). A range of learning and 
behavioral disorders (e.g. attention-deficit hyperactivity disorder and autism) has been 
consistently observed in some, though not all, boys with DMD (Hinton et al. 2001; Cyrulnik et 
al. 2007; Hendriksen and Vles 2008).  
 The progressive nature of the disease results in a gradual loss of ambulation with 
dependence on walking aids followed by full-time use of wheelchairs, typically in the early to 
mid-teens (McDonald et al. 1995; Biggar et al. 2006). Muscle contractures and scoliosis develop, 
further limiting abilities (Brooke et al. 1983; McDonald et al. 1995). As muscles continue to 
decline, cardiac and respiratory issues can ensue (Finder et al. 2004; English and Gibbs 2006; 
Vita et al. 2009) and usually become the cause of death in the 20s or 30s (Eagle et al. 2002; 
Brown Jr. et al. 2008). This presentation represents a common depiction of the natural history of 
DMD. Newer interventions and treatments discussed below, however, have shifted the 
progression of disease, development of scoliosis and life expectancy.  
 The progression of DMD has been generally classified into five stages: 1) pre-
symptomatic, 2) early ambulatory, 3) late ambulatory, 4) early non-ambulatory and 5) late non-
ambulatory. Though this disease course is usually predictable, variation in the onset of symptoms 
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 and overall phenotype among patients has been described (Brooke et al. 1983; Brooke et al. 
1989; Desguerre et al. 2009). Additionally, while not the topic of this work, Becker muscular 
dystrophy (BMD) is a less common, allelic condition with similar albeit later onset of symptoms 
than DMD. As better recognition of and enhanced treatments for DMD become available the 
hope is that this clinical course will continue to improve, as it has been over the last several 
decades.  
3.2 CARE RECOMMENDATIONS FOR MANAGEMENT OF DMD 
In the absence of a cure, management for patients with DMD has focused on slowing down the 
disease progression while maintaining quality of life. Given the multi-system effects DMD has 
on the body, management of the condition is complex, typically involving multiple specialists. 
The model is for individuals to access this care through a multidisciplinary clinic. Increasing 
activism on the part of parents along with advances in knowledge and technology have generated 
a shift from non-interventional to more supportive and aggressive intervention (Finder et al. 
2004; Webb 2005). 
Consensus recommendations for single-system aspects of DMD care have been 
developed, for example in respiratory (Finder et al. 2004) and cardiovascular management (AAP 
2005) and glucocorticoid use (Moxley et al. 2005). More recently Bushby et al issued 
comprehensive care recommendations for DMD in 2010 (hereafter, DMD care 
recommendations) through Centers for Disease Control and Prevention (CDC), European Union 
TREAT-NMD and patient advocacy groups and collaboration of over 80 experts (Bushby et al. 
2010a; Bushby et al. 2010b). The DMD care recommendations were published in the Lancet 
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 journal in two parts. Part 1 details diagnosis, pharmacological and psychosocial management and 
Part 2 details implementation of multidisciplinary care. The documents lay out recommendations 
for multi-system care (Figure 1) throughout five stages of DMD's course based on previous 
studies and ratings by expert opinion. The DMD care recommendations cover diagnosis, 
neuromuscular, rehabilitation, orthopedic, pulmonary, cardiac, gastrointestinal and psychosocial 
management. They emphasize the multi-disciplinary aspect essential to care of DMD, stating "no 
one aspect of the care of this disease can be taken in isolation" (Bushby et al. 2010b). 
Prior to the development of these recommendations, early treatment approaches were 
focused on developing medications to slow the progression of DMD. Glucocorticoids have 
become a standard of care for DMD through multiple studies and clinical trials over several 
decades showing delay of declines in muscle strength and function (Drachman et al. 1974; 
DeSilva et al. 1987; Mendell et al. 1989; Fenichel et al. 1991; Griggs et al. 1993; Balaban et al. 
2005; Biggar et al. 2006; Escolar et al. 2011). Benefits of treatment are observed as early as 3 
months after initiation. The two main types of glucocorticoids are prednisone and deflazacort, 
recommended at doses of 0.75mg/kg per day and 0.9 mg/kg per day, respectively, and initiated 
when boys have reached a plateau (when motor skills are neither progressing nor declining) 
(Bushby et al. 2010a). The effect of the treatment on muscles in turn delays loss of ambulation 
by 2 or 5 years and development of scoliosis as well as stabilizes lung and heart function 
(Balaban et al. 2005; Biggar et al. 2006; Manzur et al. 2008; Moxley et al. 2010). Because of the 
latter benefits, continuation of glucocorticoids after ambulation loss is frequently practiced 
(Bushby et al. 2010a). Reduction in strength loss and preservation of functional capacities and 
lung function were recently shown to be preserved with chronic use of glucocorticoids 
(Henricson et al. 2013). Treatment side effects can be significant and include weight gain, 
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 cataracts, behavioral changes, cushingoid facies, gastrointestinal complications and bone 
demineralization (Fenichel et al. 1991; Balaban et al. 2005; Biggar et al. 2005). A completed trial 
by CINRG (Escolar et al. 2011) and a continuing trial by the National Institutes of Health (NIH) 
(Griggs 2013) are aimed at determining ways to reduce side effects via different regimens (e.g. 
daily versus weekend) and assessing any differences in benefit between prednisone and 
deflazacort. 
 Other key interventions in DMD include physical therapy and assistive devices (splints, 
orthotics, standing devices) to maintain muscle flexibility and elongation and to prevent 
contractures (Brooke et al. 1989; McDonald et al. 1995; Bakker et al. 2000; Case 2006). Night 
splints, also called ankle-foot orthotics, are worn at night to prevent development and/or 
progression of contractures. After ambulation is lost, manual and power wheelchairs help 
individuals to maintain independence (Sussman 2002; Webb 2005). Spinal fusion may be 
indicated for scoliosis though the need for this surgery has been reduced as glucocorticoid use 
has become standard of care (Biggar et al. 2006; Moxley et al. 2010). Surgical interventions for 
contractures may also be indicated (Rideau et al. 1995; Sussman 2002).  
 Routine monitoring and ventilatory interventions, including cough assist, non-invasive 
nighttime ventilation and eventually daytime non-invasive or invasive ventilation address 
declining respiratory function (Eagle et al. 2002; Jeppesen et al. 2003; Finder et al. 2004).  
Cough assist devices aid in clearing the airway to prevent infection and collapse of the lungs. In-
exsufflator devices, for example the Emerson Cough Assist device, mechanically simulate a 
cough for users. The DMD care recommendations strongly supports use of this type of device. 
Devices or approaches to move mucus, typically used in conjunction with cough assist devices, 
include intrapulmonary percussive ventilation (IPV), chest percussion, percussive nebulizer, and 
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 pulmonary vests. Non-invasive ventilation devices, such as nasal intermittent positive pressure 
ventilation (NIPPV) with bi-level positive airway pressure (Bi-PAP) are recommended for DMD 
(Finder et al. 2004). Other non-invasive therapies such as continuous positive airway pressure 
(CPAP) and negative pressure ventilators are of limited use or should be used in a cautious 
manner. Tracheotomy is an example of invasive ventilation that should be considered if non-
invasive techniques are not possible or feasible along with consideration of patient and family 
preference.  
 Cardiac care involves monitoring of function and treatment of complications 
(cardiomyopathy, arrhythmia) with standard cardiac medications including angiotensin-
converting enzyme (ACE) inhibitors as well as beta-blockers and anti-diuretics (AAP 2005; 
English and Gibbs 2006). Psychosocial support for both the individual with DMD and his family 
is also indicated to address behavioral and emotional difficulties that arise through the course of 
living with DMD (Green and Murton 1996; Nereo et al. 2003; Abi Daoud et al. 2004). 
Increased survival over time has been attributed to a number of factors including 
improved organization and delivery of care, use of flu immunizations and antibiotics, physical 
therapy, ventilatory support, scoliosis surgery and glucocorticoids (Eagle et al. 2002; Jeppesen et 
al. 2003; Bourke 2006; Kenneson et al. 2010).  As care and interventions have improved so has 
lifespan, requiring more attention to be paid to previously less common complications, including 
those involving the heart and gastrointestinal tract (Baxter 2006; Manzur and Muntoni 2009). In 
addition, as more boys with DMD enter adulthood, attention has shifted toward improving the 
transition to adult care and including higher education and vocation training in long term plans 
(CDC 2009; Manzur and Muntoni 2009; Romitti et al. 2009). Increased awareness of palliative 
and end-of-life care for these families has been discussed (Finder et al. 2004; Madsen 2009; 
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 Bushby et al. 2010a; Cohn 2010; Arias et al. 2011). The family is a key component in the care 
and support of individuals with DMD (Bostrom et al. 2006). Thus, recognition of the needs of 
the family as a unit is also important. 
 With the establishment of the DMD care recommendations and increased collaboration 
across interested stakeholders, current efforts are focused towards implementation of the care 
recommendations and improved access to care across multi-disciplinary sites. Through the 
collaboration of multiple non-profit organizations, family-friendly guides of the DMD care 
recommendations have been created in over 25 languages and are available for download from 
the Internet (http://www.treat-nmd.eu/care/dmd/family-guide/). Patient registries and initiatives, 
discussed further below, have also been developed to assess levels of care received, enhance 
family’s knowledge and choices in DMD care, promote adoption of DMD care recommendations 
at clinics and establish centers of excellence in DMD care. 
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Figure 1: Interdisciplinary management of DMD 
The core areas of management are shown above with the patient and family at the center of care. Figure from 
(Bushby et al. 2010a) and used with permission from Elsevier Limited.  
ABG=arterial blood gas. ACE=angiotensin- converting enzyme. DMD=Duchenne muscular dystrophy. 
Echo=echocardiogram. ECG=electrocardiogram. GC=glucocorticoids. GI=gastrointestinal. MEP=maximum 
expiratory pressure. MIP=maximum inspiratory pressure. PCF=peak cough flow. ROM=range of motion.  
3.3 IMPACT OF CHRONIC DISEASES AND DMD ON FAMILIES 
The burden of having a child with disabilities can be significant for families. Approximately 
20% of families with a child with special healthcare needs report that they have financial 
problems as a result of their child’s needs (Kuhlthau et al. 2005; Chen and Newacheck 2006). 
Children with chronic health conditions, including muscular dystrophy, have been shown to 
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 require anywhere from 2 to 20 times the costs for medical care when compared to the general 
population of children (Ireys et al. 1997; Kuhlthau et al. 2005; Ouyang et al. 2008). Such 
families are more likely to have out-of-pocket expenses related to their child’s health needs 
(Anderson et al. 2007; Shattuck and Parish 2008).  
 Studies have associated having a child with special healthcare needs, including DMD, 
with diminishments in parental employment and mental health with increases in stress and 
distress (Polakoff et al. 1998; Kuhlthau et al. 2005; Bostrom et al. 2006; Chen and Clark 2007; 
Witt et al. 2009; Chen and Clark 2010; Kenneson and Bobo 2010). About 30% of families of 
children with special healthcare needs said they cut back or stopped working due to their child; 
this was likelier to be the case in lower income families (Chen and Newacheck 2006). 
Demographic characteristics associated with families with a child with a disability include lower, 
single income and higher likelihood to live in lower quality housing and in poverty (Anderson et 
al. 2007). Having a medical home, insurance coverage and access to community-based services 
are all associated with improved finance outcomes in these families (Kuhlthau et al. 2005; Chen 
and Newacheck 2006). A case-control study found higher risk for a depressive episode in parents 
of a child with DMD; single parenthood and older child ages were also found to be risk factors 
for distress and lower feelings of control in these parents (Abi Daoud et al. 2004).  
 The literature is replete with studies investigating quality of life, progression of clinical 
features and potential new therapies in DMD. There are few studies, however, attempting to 
depict the impact of DMD on families from an economic and healthcare utilization perspective. 
Compared to other common neuromuscular disorders, DMD was shown in one report to have the 
highest annual outpatient rehabilitative costs, the bulk of which came from wheelchair and other 
equipment needs (Koch et al. 1986). Chen et al found that family functioning was not 
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 significantly correlated with the child’s disability level, income or employment variables (Chen 
and Clark 2007). 
Several recent studies have examined the socioeconomic burdens associated specifically 
with muscular dystrophy. Total medical care expenditures for a privately insured US population 
of families of a member (aged 30 or less) with muscular dystrophy were 13 times higher than a 
comparison population without muscular dystrophy (Ouyang et al. 2008). Another US study 
found that children with muscular dystrophy had more functional, emotional and behavioral 
problems as well as mobility and durable medical equipment needs than children with special 
healthcare needs without muscular dystrophy (Ouyang et al. 2012). Factors associated with being 
less likely to have a medical home in children with muscular dystrophy were being non-White, 
non-Hispanic; lower than high school parent education; income below the poverty line; no or 
public insurance; and single-parent household (Ouyang et al. 2012). Families of children with 
muscular dystrophy were more likely to be on public insurance; come from lower income and 
education households with financial problems and reduction in work hours; have more than 10 
hours of care from family per week; and have out-of-pocket costs than children with special 
healthcare needs without muscular dystrophy (Ouyang et al. 2012).  
3.4 HEALTHCARE UTLIZATION IN DMD 
Several small studies, some of which are dated, have examined aspects of healthcare utilization 
and perceptions in DMD from the perspective of the family. Bothwell et al surveyed 31 families 
and found that treatments and issues related to preserving walking ability were most important, 
particularly in those with younger boys while those with older boys also felt that mental health 
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 issues and services were very important (Bothwell et al. 2002). Arias et al surveyed 34 families 
of older males with DMD (ages 12 to 34) about palliative care services. They found that the 
majority of respondents had utilized respiratory care while 40% or less used nutrition, social 
work, or mental health services (Arias et al. 2011). Koch et al found that families who lived 
longer distances away from a Muscular Dystrophy Association (MDA) clinic (even with 
reimbursement for travel) tended to not make all their appointments and possibility underutilized 
available services (Koch et al. 1986). One of the major categories of problems U.K. parents of 
children with DMD experienced was in getting needed services and covering medical expenses 
as well as feeling dissatisfaction with services that were obtained (Firth et al. 1983). Another 
study found that patients and parents felt that psychosocial services and life expectancy 
information were important but felt this need was unmet; in contrast, healthcare providers at the 
same clinics reported more availability of such services (Madorsky et al. 1984). A Canadian 
study that included parents of children with DMD (as well as several other common chronic 
conditions) found that parents placed importance on providers’ knowledge and interaction with 
their child; communications among providers about their child; and non-compartmentalization of 
services (Miller et al. 2009). 
Recently, assessment of service and intervention use in families with DMD has been 
initiated through patient registries. DuchenneConnect, a registry created by Parent Project 
Muscular Dystrophy (PPMD), was started in late 2007 to “bridge the information gap between 
care providers, researchers and the patient community, thereby addressing medical care needs 
and accelerating the pace of therapeutic advancements” (Rangel et al. 2012). Parents and 
individuals with DMD, BMD, intermediate muscular dystrophies as well as carriers for these 
conditions can create a profile and give information on health services, devices, and medications 
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 they use. As of the end of 2012, the registry had over 2,000 completed profiles 
(DuchenneConnect 2013). 
The MDA announced plans in October 2012 to launch a national clinician-entered patient 
registry for three diseases, one of which is DMD, in 25 pilot clinics (Wolff 2012). A formal 
proposal was recently published in the journal Neurology (Scully et al. 2013). The registry aims 
to record clinical and health-outcome data from MDA clinic participants in the hopes of 
improving clinical practices, understanding of natural history and genotype-phenotype 
correlations and patient eligibility for clinical trials. A system of public reporting of clinic 
outcomes across MDA clinics is predicted to improve implementation and standardization of 
DMD care recommendations. This proposal cites the precedent set by the Cystic Fibrosis 
Foundation’s registry system which has been credited with increased survival and improved 
outcome measures among patients (Scully et al. 2013). 
Information from these registries is important for determining future directions needed in 
care. Transforming Duchenne Care (Cripe 2012; Kinnett 2012) is a PPMD initiative involving 
collaboration between PPMD and MDA with input from physicians, other healthcare providers 
and patient representatives. The initiative has the aim of promoting clinic transparency and 
adoption of DMD care recommendations and improving care delivery in North America. A long-
term goal is to develop a Network of Duchenne Centers of Excellence based on consensus of an 
ideal model of care delivery for DMD along with insights gained from practices in the CF 
community, as mentioned above. 
Similar efforts have been undertaken abroad. The European-based TREAT-NMD seeks 
to harmonize key clinical data (including some measures of medication and procedure use) from 
patients with confirmed DMD diagnoses in national patient registries into a global database 
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 (TREAT-NMD 2013). Associated with TREAT-NMD is CARE-NMD, a collaboration of several 
European countries that seeks to enhance implementation of DMD care recommendations at care 
centers, assess patient quality of life and improve patient participation in national registries 
(CARE-NMD 2013). Alongside these efforts, focus has been aimed at determining what health 
indicators are useful in assessing quality of care in rare diseases, particularly in patient registries 
(EUCERD 2011). 
3.5 NATIONAL INITIATIVE FOR FAMILIES WITH DUCHENNE (NIFD) SURVEY 
The Cooperative International Neuromuscular Research Group (CINRG) is a consortium of 
medical and scientific investigators from academic and research centers facilitating 
neuromuscular disorder research. Founded in 1999, CINRG focuses on clinical research in 
DMD. Since then, the network has expanded to over 25 US and international sites and runs 
observational studies and clinical trials for neuromuscular disorders.  
 NIFD was developed in collaboration between researchers at Children’s National 
Medical Center (CNMC) and Columbia University with funding from the CDC and American 
Association of Medical Colleges. As the first large-scale survey of DMD families in the US, 
NIFD was a lengthy cross-sectional survey developed to cover the following topics: family life 
(demographics, life events, home adaptation); child’s health, medical care and schooling; 
diagnostic process; and impact on family (Figure A12). Families with a male child with DMD 
were eligible to take the survey. The aim of this survey was to capture what services families 
were receiving and the impact of DMD on their lives with the purpose of identifying gaps in 
DMD care and giving direction to future programs.  
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  Data were collected between 2006 and 2009 from 235 respondents who took the survey 
in one of two formats: a paper version (n=121) and a web-based version (n=114). The paper 
version was completed as a baseline survey for US participants in CINRG’s DMD Natural 
History Longitudinal Study: Relationship between Impairment, Activity Limitation, Participation 
and Quality of Life in Persons with Confirmed Duchenne Muscular Dystrophy (DMD), hereafter 
called the CINRG DMD Natural History study (McDonald et al. 2013). Given the significant 
impact of glucocorticoid treatment, this study was undertaken to provide an updated natural 
history for DMD. The study enrolled over 300 males ages 2 to 30 years with DMD from US and 
international sites. The goal is to generate the largest comprehensive longitudinal assessment of 
DMD by observing participants’ physical abilities, quality of life, medical problems, healthcare 
utilization and genotype over a five-year period. Parents of participants had to be over the age of 
18. The study began in 2006 and is currently continuing active protocol visits. The study 
excluded participants who were walking past the age of 13 (without glucocorticoids) or 16 (with 
glucocorticoids) and subjects/parents unwilling or unable to participate in the study’s protocols 
and visits. Funding was recently received to extend the study for an additional three years. 
Enrollment has been re-opened to recruit a new young cohort of 4 to 7 year old boys with DMD 
and a healthy control group of males aged 6 to 30. Some of the first reports from this study are 
currently in press, including an article regarding study protocol and methods design (McDonald 
et al. 2013) and another regarding preservation of muscle and lung function with chronic use of 
glucocorticoids (Henricson et al. 2013). 
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 4.0  MATERIALS AND METHODS 
This project was reviewed by the University of Pittsburgh’s Institutional Review Board and was 
determined to meet criteria for exemption (Appendix B). Data from the NIFD survey was 
received from the data manager at the CINRG Coordinating Center at CNMC. Data from the 
DuchenneConnect patient registry was received by formal request from the project’s operations 
team. 
4.1 DATA 
4.1.1 NIFD Survey 
Raw data collected from all NIFD survey respondents were obtained as a Microsoft Excel file 
after a formal data request to CINRG’s Coordinating Center data manager. In total 235 surveys 
were completed between 2006 and 2009. The survey was completed in one of two formats: paper 
(n=121) or web-based (n=114). The NIFD paper survey was administered to US participants in 
the CINRG DMD Natural History study (n=116). An additional five respondents completed the 
paper version and mailed their survey to CNMC. 
The remaining surveys (n=114) came from respondents who completed the survey on the 
Internet via posting at SurveyMonkey.com, an online survey tool. Participants accessed the 
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 survey via announcements posted in MDA clinics and CINRG sites or by clinician invitation. It 
is possible they also may have found the survey on their own via Internet surfing. The method by 
which participants found the survey, however, was not assessed on the survey.   
The population that took the Paper version of the survey (CINRG DMD Natural History 
study and five other respondents) is hereafter referred to as the “Paper” population while those 
respondents who took the survey at SurveyMonkey are referred to as the “Internet” population. 
Forty-four (18.7%) of surveys were excluded from final analysis due to non-response, duplicate 
respondents and more than one family member being represented (see details below in Methods). 
Overall, these exclusions resulted in a total of 191 respondents used in the final analysis (n=119 
Paper respondents and n=72 Internet respondents). 
4.1.2 Differences Between Internet and Paper versions of NIFD Survey 
Overall, the differences between survey sections examined (Child’s Health and Medical Care) in 
the Internet and Paper versions of NIFD were minimal. The biggest difference was that Internet 
respondents could complete portions of the survey more than once for each child with DMD that 
they had. These responses were excluded from analysis so that each respondent was only 
representing one child with DMD.  
 Because of the ability to enter information for more than one child, the order of sections 
on the Internet version differed from the Paper version, with Family and Diagnosis sections first 
and variables on Child’s Health Status and Medical Care placed at the end of the survey. These 
latter sections were located at the beginning of the Paper version.  In addition, Internet 
respondents were not able to complete the survey or proceed in the survey if they selected “No” 
to being willing to participate in the study, living in the USA, ever having a child diagnosed with 
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 DMD or if they did not enter a US zip code or select a relationship to the child. Skip functions 
were not built into the Internet version for instances where a respondent entered “Yes” or “No” 
and subsequent questions depended on this first answer (i.e. “If yes,…” or “If no, why not?”). If 
a respondent selected “Other” for an option that had a “Specify” box to type in, the respondent 
was returned back to the page to enter a comment and typically could not proceed without 
specifying a typed answer or unchecking the “Other” category.  
 Other differences between the Paper and Internet versions included a pre-selected age or 
number ranges for questions eliciting an age or number of items/people on the Internet version. 
For example, on the Internet version, respondents could select “Less than 18”, numbers 18 to 70 
or “Greater than 70” for Parent/Guardian age while those taking the Paper survey could write in 
two digits. Some wording differences or extra definitions were given and some questions had 
variations in the options respondents could select on certain versions of the survey (Table 1). In 
the case of different response options, the data from the Paper and Internet populations were 
harmonized so that the same categories and answer types were used in analysis of the data.  
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 Table 1: Differences in NIFD Paper and Internet versions 
Variable Paper Internet 
Parent/ 
guardian 
questions 
-- (If parents are divorced and/or 
remarried, please provide 
information about the 
parents/guardians who spend the 
most time living with the child.) 
Racial 
Category 
African American African American/Black 
Caucasian White / Caucasian 
Native American/Alaskan Native Native American/Alaskan Native 
Asian or Pacific Islander Asian 
-- Native Hawaiian/Pacific Islander 
-- Other (please specify) 
Insurance 
plan for 
child 
(choose all 
that apply) 
None  No insurance / Self-pay 
Self Pay -- 
HMO HMO or managed care plan  
(where you see doctors who 
belong to a network) 
Other managed care plan 
(including preferred provider 
organizations (PPO's) and Point of 
Service (POS) plans). 
 -- 
Traditional insurance plans 
(BlueCross/BlueShield, etc.) 
Traditional insurance plans (where 
you see the doctor of your choice, 
and may have to apply for 
reimbursement)  
Medicaid/State-sponsored 
programs 
Medicaid or government-
sponsored programs 
Military Military healthcare plan 
Don't know or don't remember Don't know or don't remember 
Other (specify) Other (specify) 
Major 
expenses 
not covered 
 Durable medical equipment  Durable medical equipment 
Therapy (PT, OT, Speech) Therapy (PT, OT, Speech) 
Mental Health 
Services/Counseling 
Mental Health 
Services/Counseling 
Medicines Medicines 
-- Other (specify) 
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 4.1.3 DuchenneConnect Data 
A PDF version of the DuchenneConnect registry questions was analyzed for similarity to 
questions from NIFD. To facilitate this process, a Microsoft Excel spreadsheet was generated to 
list side-by-side similar or same questions between the surveys along with the possible answers 
from each survey. A DuchenneConnect data request was created utilizing questions that were the 
same or that could be harmonized to NIFD’s questions and submitted to the DuchenneConnect 
operations team. Data were requested for those with a diagnosis of DMD and living in the United 
States. 
The data were received for 1201 registry profiles from 2007 to 2013 from the 
DuchenneConnect operations team. The data were shared in a Microsoft Excel spreadsheet with 
counts and percentages for each question requested. Additionally, counts for current age, gender 
and ancestral background for the total population were included. 
4.2 METHODS 
4.2.1 Exclusion of NIFD Surveys from Analysis 
In total, 235 NIFD surveys were completed (n=121 Paper; n=114 Internet). Forty-four (18.7%) 
of surveys were excluded resulting in a total of 191 respondents in the final analysis (n=119 
Paper population and n=72 Internet population). The details of the exclusion process are detailed 
below and in Figure 2.  
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  Twenty-seven respondents from the Internet population were excluded from analysis 
because they did not respond to questions in the sections investigated in this study regarding 
Child’s Health and Medical Care.  
 Nine surveys (n=1 Paper and n=8 Internet) were excluded because they represented 
duplicates, meaning respondents had already taken the survey at a different time for the same 
child. Duplicate responses were determined based on zip code, child’s birthdate, race and 
ethnicity and parent/guardian ages and occupations. In determining which response set to keep, 
the two response sets for each respondent were analyzed for completeness first then for how 
recently the survey was completed (if both responses sets were similarly complete). The more 
complete or more recent surveys were kept. Five pairs of duplicate responses were from 
individuals who took both the paper version at a CINRG site through the DMD Natural History 
study and the Internet version at SurveyMonkey.com. The paper surveys were kept for four of 
these respondents owing to more completeness of answered questions or a more recent date of 
taking the survey. The Internet version of the fifth set of duplicate responses from this group was 
kept because it was more recent than the paper survey. The remaining four pairs of duplicate 
responses were from individuals who took the Internet version of the survey twice. In all four 
pairs, the more complete survey was kept for analysis.  
  Eight surveys (n=1 Paper and n=7 Internet) were excluded because respondents had 
completed the survey for more than one child with DMD in their family. In these cases, surveys 
completed for the oldest child with DMD were retained for analysis. 
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Figure 2: Inclusion process for completed surveys in final analysis 
Non-response = no response in Child’s Health and Medical Care sections; Duplicates = surveys taken two times by 
one respondent for the same child; Siblings = surveys taken by respondent who already took the survey for an older 
child in the family 
 
4.2.2 Data Cleaning of NIFD Data 
A data cleaning process was developed with the CINRG Coordinating Center data manager and 
performed on data in Excel files from survey sections pertaining to Child’s Health and Medical 
Care. The overall philosophy was to minimize making changes to or assumptions about the data 
to preserve respondents’ replies (and to avoid making a question unreliable) while noting skip 
patterns or unusual responses to questions. If a Yes/No question asking if a child used a service 
Duplicates:  
9 surveys 
n=1 Paper 
n= 8 Internet 
 235 completed surveys n=121 Paper 
n=114 Internet 
 
 
 
Non-response:  
27 surveys 
n=0 Paper 
n=27 Internet 
 
 
Siblings:  
8 surveys 
n=1 Paper 
n= 7 Internet 
 
Final analysis:  
191 surveys 
n=119 Paper 
n=72 Internet 
 
Excluded surveys (n=44) 
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 or device was blank but information was entered in corresponding “If yes” questions or if an 
answer was entered for the “If no” question, the blank Yes/No variable was changed to “Yes” or 
“No”, respectively. Unusual or implausible answers or patterns were noted though not 
necessarily changed. For example, this would include a respondent who said their child took 
every type of heart medication listed. In addition, if a respondent wrote in an answer in an 
“Other, Specify” box that was already an available answer option, then the response was changed 
to the available answer option. 
For the Internet population, the age at first doctor or health professional visit variables 
were determined to be unreliable due to entered ages exceeding the child’s current age. The data 
were received from the CINRG Coordinating Center with these conflicting values and were 
excluded from the analysis. 
The date the survey was taken was used with the child’s birthdate to determine child’s 
age. For four Paper respondents, the date of survey was unable to be determined and a blanket 
date was estimated based on responses that elicited the child’s age at procedures or provider 
visits. 
 Scales used for responses between the Paper and Internet population were harmonized so 
that the same categorization of variables was used across both populations to address slight 
variations in the way answer options were listed. Because not all respondents answered every 
question, n values representing the total number of respondents specific to that question are 
given in the Results section. 
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 4.2.3 NIFD Data Analysis 
IBM’s SPSS Statistics version 21 software package was used for analysis. For Aim 1, descriptive 
statistic functions were used to describe survey variables for the entire dataset as a whole (i.e. 
Paper and Internet populations combined). Categories were created for some variables to gain an 
overall picture of the data. For instance, categories for key age groupings based on standard 
disease course were created from child’s age. For a question regarding walking ability, four 
categories were created by collapsing 10 possible responses into four similar groups. For some 
questions using ordinal responses measuring frequency, categories were combined. For instance, 
responses regarding worry or concern for the child’s physical, emotional and behavioral health 
were grouped from five (None, A little bit, Some, Quite a bit, A lot) to three categories (None, A 
little bit/Some, Quite a bit/A lot). For questions where respondents could check all answers that 
applied, an additional variable was created to assess how many respondents selected at least one 
of the possible responses. Examples of these variables include: diagnoses other than DMD, 
major expenses not covered by health insurance, use of lung clearance and assisted ventilation 
devices.  
 For Aim 2, significant differences between Paper and Internet population demographic 
variables were analyzed using Fisher’s exact 2-sided test (alpha set at 0.05) for categorical 
variables (e.g. respondent’s relationship to child; parent/guardians’ education and employment 
statuses; child’s race and ethnicity) and independent-samples t-test of means (alpha set at 0.05) 
for scale variables (e.g. parent/guardians’ ages and child’s age).  
 To capture education and employment factors of the household or family unit 
representing each child, the highest education level and the combination of work statuses among 
parent/guardian pairs were generated. To analyze other non-demographic variables with more 
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 than two possible answers between the two populations, dichotomous categories were created. 
For example, quality of healthcare responses were collapsed into two categories: “High quality” 
and “Less than high quality”.  
 Since multiple responses were possible on insurance plans several modifications were 
made to analyze differences between the populations. Eight respondents who selected no 
insurance types among all choices were considered as non-responses and excluded from analysis. 
For each plan type, respondents who did not select the type were coded as 0 (No) while coding 
for those who selected a plan (1) was retained. 
 For Aim 2, a partial correlation table controlling for survey population was generated and 
color-coded to identify associations between variables. Demographic, 
worry/limitations/satisfaction, child health status, healthcare quality and understanding, and 
selected provider variables were analyzed for associations with most variables examined in the 
survey sections under study (Child’s Health and Medical Care).  A two-tailed significance p-
value of ≤ 0.10 and correlation value ≥ 0.30 was considered significant.  
 Forward and backward linear regression models were generated for two dependent 
variables (frequency of pain/discomfort for the Paper population and overall life satisfaction for 
both populations). Data from the Internet population on frequency of pain/discomfort was not 
available. First, potential independent variables were selected by using those identified in the 
correlation table with significant correlations to the dependent variable. Second, to avoid 
including independent variables with correlations to each other in regression modeling, variables 
of interest that were also unrelated to each other were selected.  
 Using this approach, the following were set as independent variables for the outcome of 
frequency of pain/discomfort: child’s limitations due to health problems, use of albuterol for 
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 strength, use of proton pump inhibitors, use of manual wheelchair, seeing a cardiologist and 
child’s satisfaction with school ability.  The following were set as independent variables for the 
outcome of child’s overall life satisfaction:  child’s satisfaction with friendships, use of attention 
deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD) medications, child’s health 
other than DMD, walking independently and respondent’s worry or concern regarding child’s 
behavior.  In addition, survey population was included as an independent variable for child’s 
overall life satisfaction. Regression modeling p-values ≤ 0.10 were considered significant.  
4.2.4 Harmonization of Data between NIFD and DC Populations 
For Aim 3, data between the two surveys was first harmonized by generating comparable 
categories for similar questions. Demographic information on DuchenneConnect data included 
current age, gender, and racial background. Thus it was not possible to determine if DC 
respondents were related to each other or how other demographic factors compared between the 
NIFD and DC populations. It was also not possible to determine if there were respondents who 
completed both the NIFD and DC profiles. 
 DC data included the first choice selected by participants for one question on 
racial/ethnic background. NIFD racial and ethnic data (originally two separate questions with 
only one answer allowed) were combined into one variable to match that of DC, whose survey 
had Caucasian/Hispanic and Caucasian/Not Hispanic among other possible responses. 
Combining these NIFD variables excluded five respondents who specified either race or 
ethnicity but not both (e.g. Caucasian with no response on Hispanic origin; Hispanic or non-
Hispanic with no race selected).  
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  Co-occurring diagnoses other than DMD were compared. There were differences in 
wording of some conditions. For example, “global developmental delay” and “speech/expressive 
language delay” on DC versus “developmental delay” and “speech delay” on NIFD. There were 
also a larger number of diagnoses queried on the DC profile. Similarly, for medical expenses, 
NIFD respondents who had health insurance for their child were asked “what major expenses 
have not been covered by the plan” versus DC participants who were asked about expenses they 
have “problems getting reimbursed by insurance or obtaining approval”. Data for these questions 
was compared for “Medications” and “Durable Medical Equipment” (NIFD) and “Medicines” 
and “Devices or equipment” (DC).  
 To harmonize insurance type data, DC data for “Medicaid” and “Medicare/Medicare 
advantage” were combined to compare to NIFD’s “Medicaid/State sponsored programs” count. 
Similarly, DC data for “Private/individual” and “Commercial/employer” were combined to 
compare to a combined count of NIFD’s “Traditional insurance plans” and “HMO/Other 
managed care plan”. “No insurance” (DC) and “No insurance/self-pay” (NIFD) and “Military” 
(same for both surveys) categories were directly compared between populations. An “Other” 
category was created for both populations. For DC this included selections of “Prefer not to 
answer”, “National Health Programs” and “Other US federal programs”. For NIFD, the “Other” 
category included an “Other” option from the survey.  
 Walking ability data from NIFD were harmonized with DC’s response categories for how 
participants get around outside the home. NIFD respondents could select one of eleven possible 
choices for typical walking ability that touched on walking in and outside home. Seven of these 
choices ranging from “Cannot take any steps at all (primarily uses power wheelchair)” to “Walks 
for 15-50 feet but only inside at home” were coded as DC’s  “I use a wheelchair or other 
 29 
 mobility device and rarely or never walk”. Three NIFD choices indicating ability to walk outside 
the home with varying requirements for assistance were coded as DC’s “I get around without a 
wheelchair or scooter but I need help”. The remaining NIFD choice indicating full walking 
ability without assistance was coded as DC’s “I usually walk on my own and I don’t need help or 
assistive devices”. 
 Use of therapies, equipment and medications was directly compared for the most part 
between NIFD and DC data. For glucocorticoid use, NIFD respondents reporting their child’s 
use of at least one of prednisone, prednisolone or deflazacort were included in a 
“Glucocorticoids used” category. Similarly, DC respondents who reported they were currently 
using deflazacort or prednisone or who reported past use of glucocorticoids were included in a 
“Glucocorticoids used” category.  The DC profile asked about current use of wheelchair types 
(choose all that apply) whereas NIFD asked if patients had ever used these devices. To 
harmonize to DC data, NIFD data on manual and power wheelchair use were combined into one 
variable. Those who only reported having used a manual wheelchair were coded as manual 
wheelchair while those who reported having used a power wheelchair only or both manual and 
power were coded as power wheelchair. This assumed for both datasets that an individual would 
not use a manual wheelchair once they had used a power wheelchair. Use of splinting was 
compared between the two surveys, which used different terminology for the same device: “night 
splints” on NIFD versus “AFOs (ankle-foot orthotics)” on DC. Lastly, to harmonize to DC’s 
question regarding use of any breathing devices, a variable capturing use of at least one breathing 
device was generated for NIFD data. DC data on three different Bi-PAP usage scenarios was 
collapsed into one variable to reflect overall use of a Bi-PAP device.  
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 4.2.5 DuchenneConnect Data Analysis 
For Aim 3, descriptive statistics were generated for the DuchenneConnect population. For most 
DC variables, data on how many total participants responded to a question were not available. 
Therefore, for these questions percentages were generated by dividing total respective survey 
population (N=1201) by the total count of a particular variable. This same method was used on 
NIFD data when comparing variables between populations.  
Respondents for both surveys were able to select as many insurance types that applied. 
Because several insurance types were combined for harmonization of data, these responses were 
analyzed by examining percentage of insurance types selected among the total number of 
selections made by respondents. Significant differences between population variables were 
determined by Fisher’s exact 2-sided test or independent-samples t-test of means, both with 
alpha set at 0.05. The t-test was performed using SPSS software. Fisher’s tests were calculated 
using an online calculator available from GraphPad Software at http://graphpad.com/quickcalcs.  
DuchenneConnect collects date of birth, gender, and racial/ethnic background as part of 
an account registration that is separate from the patient’s profile containing questions regarding 
use of services, medications and equipment. There were 23 DC registrants in a lumped age 
greater than 40 years category and 22 with reported female gender. Consultation with the 
DuchenneConnect Coordinator indicated that these responses are likely from parents (of a person 
with DMD) who filled out account registration with their personal date of birth and gender but 
filled out the patient profile section with their son’s information. Thus, the ages greater than 40 
years category was excluded in calculating descriptive statistics on age of individuals with DMD 
from the DC population. Gender was also assumed to be male for the DC population.  
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 5.0  RESULTS 
5.1 DESCRIPTION OF NIFD DATASET 
Summary statistics were described for survey questions regarding demographics; health status of 
the child with DMD; general healthcare usage and quality; use of providers, services, equipment, 
medications, complementary/alternative medicine and procedures; and worry, satisfaction, 
limitations due to DMD. A subset of variables is described below. The remaining data 
description is located in Appendix C. 
5.1.1 Demographics 
The majority (79.7%; n=149) of survey respondents were biological mothers. Other relationships 
selected by respondents are shown in Figure 3. In the “Other “category, there was a sister and 
one individual with DMD who completed the survey by himself. There were no respondents who 
selected foster mother, stepfather or stepmother. 
 The survey elicited age, education and employment status for two parents/guardians 
(n=382 possible responses). The combined average age of both parents/guardians was 42.2 years 
(SD ± 8.5; range 20 to 66 years; n = 359). Among both parents/guardians, 40% had a bachelor’s 
degree, some graduate schooling or held a graduate or professional degree. The majority were 
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working full time. Roughly half of families’ annual income was less than or equal to $74,999. 
The distribution of parent/guardian ages and other demographic variables are shown in Table 2. 
The mean age of the children with DMD for whom the survey was taken was 11.2 years 
(SD ± 6.1; range 1 to 28 years; n = 189). The median age was 10 years. Almost 70% of children 
had used glucocorticoids. The distribution of ages and glucocorticoid use are shown in Table 3. 
Most children were Caucasian and non-Hispanic background (Table C17). 
Figure 3: Respondent's relationship to child 
Table 2: Respondent and Family Demographics 
Demographic Characteristic 
Parent/Guardians’ 
Age*, range in 
years (n) (total 
n=359) 
Parent/Guardians’ 
Education* (n) 
(total n=358) 
Parent/Guardians’ 
Employment* (n) 
(total n=352) 
Annual Family 
Income (n)  (total 
n=185) 
* Respondents were able to enter age, education and employment status for two
parent/guardians. Total possible n for combining these two variables =382. 
5% 
37% 
36% 
19% 
3% 
20 to 29 (17) 
30 to 39 (134) 
40 to 49 (131) 
50 to 59 (67) 
60 to 66 (10) 
4.7% 
18.4% 
36.9% 
22.9% 
17.0% 
< HS Diploma (17)
HS Diploma (66)
Some/Two-Year College (132)
Bachelor’s Degree (82) 
Some Grad or
Grad/Professional Degree (61)
15.9% 
13.1% 
71.0% 
Not Working
(56)
Part-time (46)
Full-time (250)
2.7% 
14.1% 
14.6% 
17.8% 24.9% 
24.3% 
1.6% 
<$10,000 (5)
$10,000 – 34,999 (26) 
$35,000 – 49,999 (27) 
$50,000 – 74,999 (33) 
$75,000 – 99,999 (46) 
$100,000 – 199,999 (45) 
≥$200,000 (3) 
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Table 3: Child Demographics 
Demographic Characteristic 
Child Age, 
range in years (n) 
(total n=189) 
Glucocorticoid Use (n) 
(total n= 178) 
* Respondents selecting “Yes” to the question “Has your child used the following” for at
least one of the medications 
5.1.2 Health Status of Child with DMD 
Among 189 respondents, 57.1% (n=108) said their child was able to walk independently. Of 184 
respondents who selected a statement that best summarized their child’s typical walking ability, 
38.1% (n=70) said their child was not able to take any steps at all and primarily used a power or 
manual wheelchair. 11.4% (n=21) could only walk for varying short distances in the home or at 
school with assistance. 41.3% (n=76) were able to walk outside the home but with varying levels 
of assistance. Meanwhile, 9.2% (n=17) said their child walks, runs and climbs without difficulty 
or assistance.  
Respondents were asked to select how often their child experienced pain or body 
discomfort during the past month (Figure 4). Data were only available for this question from the 
18.0% 
30.2% 
20.1% 
14.3% 
17.5% 
1 to 5 (34)
6 to 9 (57)
10 to 13 (38)
14 to 17 (27)
≥18 years (33) 
30.3% 
69.7% 
No
glucocorticosteroid
(54)
Prednisone,
Prednisolone
and/or Deflazacort
(124)*
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Paper population. Almost 75% experienced bodily pain or discomfort during this time period; 
about a third experienced it weekly or daily. Respondent’s rating of the quality of their child’s 
health other than the diagnosis of DMD are shown in Figure 4. Over 75% of children felt their 
child’s health was excellent or very good. No respondents selected “Poor” for this question.  
Respondents were able to select “Yes”, “No” or “Don’t Know” for each of nine 
conditions other than DMD that their child had been diagnosed with by a doctor or other 
professional. Of 189 respondents, about 57% (n=109) said their child had been diagnosed with at 
least one of these nine conditions. Data from respondents who answered “Yes” for the conditions 
are shown in Figure 5. Respondents were also able to select “Other” and specify an additional 
condition (Table C18). 
Figure 4: Child's pain frequency and health other than DMD  
Left: Frequency of bodily pain or discomfort in the past month among Paper population (n=115); Right: Rating of 
child's health other than DMD in both populations (n=184) 
26.1% 
40.0% 
14.8% 
19.1% 
Frequency pain & discomfort in 
Paper population (n=115) 
Never (n=30)
1-4 times/month
(n=46)
1-2 times/week
(n=17)
Every day or
almost every
day (n=22)
31.2% 
45.5% 
19.0% 
4.2% 
Child's health other than DMD 
(n=184) 
Excellent
(n=59)
Very Good
(n=86)
Good (n=36)
Fair (n=8)
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Figure 5: Diagnoses other than DMD 
Respondents could select “Yes”, “No” or “Don’t know” for 9 conditions in response to the question “Have you ever 
been told a doctor or other professional that your has…”. Data shown above are for those who responded Yes for 
each condition. Total number of responses for each diagnosis are shown in bars. DD = Developmental delay; 
ADD/ADHD = Attention deficit; Vision/Hearing = Impairment; MR = Mental retardation; PDD = Pervasive 
developmental disorder 
5.1.3 General Healthcare Coverage, Understanding and Quality 
Health insurance plans for the child with DMD are shown in Figure 6. Respondents could select 
as many plans types as applied. Thirty-seven to 44% of respondents (n=67-80) selected 
traditional, HMO/other managed care plans and/or Medicaid/State program plans. Two to 4% 
(n=4 to 7) selected None/self pay, Other and/or Military plans. For those with health insurance 
for their child, respondents were asked to select as many major expenses that were not covered 
by the plan as applied from a prescribed list. 84 respondents (44%) from the total survey 
population (N=191) selected as least one expense that was not covered (Figure 7). Over two-
thirds of the selections made by this group were related to durable medical equipment and 
therapy (PT, OT, Speech) expenses. 
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To assess perceived knowledge of DMD, respondents were asked, “How well do you 
think you understand how DMD is inherited, whether future children might inherit it and the 
kinds of service needed?”. Over 60% (n=115) felt they knew these aspects of care very well 
while 34% (n=65) felt they knew somewhat well (Figure 8). The survey did not ask questions 
about DMD to assess actual knowledge of these areas.  
Since the child’s diagnosis with DMD the overall quality of healthcare received by the 
child is shown in Figure 8. Over half of respondents felt their healthcare was high quality. 
Respondents were able to write or type in additional comments about the quality of healthcare 
received by their child since diagnosis. Forty-four respondents (23% of the total survey 
population) gave comments, which are detailed in Appendix C.3.2. Several themes emerged 
from respondents’ comment including praise for care, dissatisfaction with clinic logistics and/or 
doctors, and difficulty getting access to particular therapies.  
Figure 6: Health insurance plans for child with DMD 
Shown are responses from 182 respondents who were able to choose all health insurance plans that applied to their 
child.  
44.0 
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Figure 7: Major expenses not covered by health insurance plan 
Respondents could select as any of the expenses types that applied. Shown are the percentages of 122 selections of 
major expenses not covered that were selected by 84 respondents (44% of total survey population). PT = physical 
therapy; OT = occupational therapy. 
Figure 8: Overall quality of healthcare and respondents' understanding of DMD 
Very 
well(115) 
60.5% 
Somewhat 
well(65) 
34.2% 
Not very 
well(10) 
5.3% 
Respondent's Understanding of 
DMD (n=190) 
Less than 
adequate 
(11) 
6.0% 
Varied 
(14) 
7.7% 
High 
quality 
(94) 
51.6% 
Adequat
e (63) 
34.6% 
Overall quality of healthcare 
since DMD diagnosis (n=182) 
37.7% 
32.8% 
18.0% 
11.5% 
Major expenses not covered by health 
insurance plan (n=122 selections) 
Durable Medical Equipment (n=46)
Therapy (PT, OT, Speech) (n=40)
Medicines (n=22)
Mental Health Services/Counseling n=(14)
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 5.1.4 Healthcare Providers 
 A multidisciplinary approach for care was suggested in that most children saw a neurologist 
followed by a large percentage seeing a cardiologist, pulmonologist and physical therapist 
outside of school (Table 4). Other providers seen are shown in Table 4. The age at first visit in 
years is shown for the Paper population for selected providers (Table 5); responses from the 
Internet population for this question were excluded from analysis due to unreliability of data (see 
Methods, Data Cleaning). Mean ages at first visit for the neurologist and physical therapist were 
5 and 6 years, respectively. Mean ages at first visit for the cardiologist and pulmonologist were 
older at 9 and 11 years, respectively. 
 Reasons why children did not see a particular doctor or health professional are shown in 
Table 6 and Figure 9 for selected providers. For all providers, the largest percentage of 
respondents selected the reason “Child does not need this service”. About 75% or more of these 
children were ages six years and older (Table 7).  A handful of respondents’ children in these 
tables may have seen the provider in the past based on concomitant responses of “Yes” to seeing 
the provider and/or giving the age of the child at first visit; thus their responses in the table may 
reflect why their child was not currently seeing that provider despite having seen them in the 
past.  
 Respondents were asked in a separate section of the survey if a genetic counselor or 
geneticist helped “define your risk of having additional children affected by DMD”. Using this 
question as proxy for seeing these providers, 61.1% (n=113) of those who responded to this 
question (n=185) saw a genetic counselor or geneticist.  
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 Table 4: Doctors or health professionals seen by child 
 Doctor or Health Professional* 
 Count 
(Yes) 
Count 
(No) 
Total 
Response a 
Percentage 
(Yes/Total 
Response) 
Neurologist  154 28 182 84.6 
Cardiologist 129 52 181 71.3 
Pulmonologist 94 85 179 52.5 
Physical therapist b 90 91 181 49.7 
Nutritionist 48 131 179 26.8 
Physiatrist 46 132 178 25.8 
Occupational therapist b 45 133 178 25.3 
Social worker 41 139 180 22.8 
Gastroenterologist 29 149 178 16.3 
Mental health therapist 29 151 180 16.1 
Speech therapist b 15 162 177 8.5 
* Respondents were asked “Does your child see the following doctor or health professional? (Yes/No)” 
a Total response from 191 possible respondents 
b therapist seen outside of school 
 
 
Table 5: Age at first provider visit for selected providers (Paper population) 
 Provider 
Mean Age,  
years ± SD * 
Range (years) Total responses 
Age at visit  
% (n) seeing 
doctor  
(of n=119) 
Neurologist  5 ± 3 <1 - 20 79 76.5 (91) 
Cardiologist 9 ± 5 <1 - 23 78 68.1 (81) 
Pulmonologist  11 ± 5 2 - 22 58 51.2 (61) 
Physical therapist a 6 ± 3 1 - 18 43 40.3 (48) 
* Respondents were asked “How old was your child at the first visit” and could write in year and month values; 
only year values are shown. Data were only analyzed for the Paper population (total population= 119). 
a therapist seen outside of school 
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 Table 6: Reasons why child did not see selected providers 
Provider* 
Total 
response 
None 
available 
% (n) 
Too 
expensive 
% (n) 
Concern 
about 
medical 
insurance 
% (n) 
Child 
does not 
need this 
service % 
(n) 
Other % 
(n) 
Neurologist 25 8 (2) 0 (0) 0 (0) 68 (17) 24 (6) 
Cardiologist 45 2.2 (1) 0 (0) 0 (0) 77.8 (35) 20 (9) 
Pulmonologist 77 2.6 (2) 0 (0) 0 (0) 72.7 (56) 24.7 (19) 
Physical therapist a 78 12.8 (10) 12.8 (10) 14.1 (11) 32.1 (25) 28.2 (22) 
* “Religious reason” was an additional answer option but no respondent selected this answer for any provider type 
a therapist seen outside of school 
 
Table 7: Age at time of survey for children who did not see a provider due to not needing the service 
Provider  
% (n) by age category of those who did not see a doctor 
for the reason “Child does not need this service”  
Total count % of 
total survey 
population 
(N=191) 
1 to 5 
years  
6 to 9 
years 
10 to 13 
years 
14 to 17 
years  
≥ 18  
years 
Total 
Count 
Neurologist 0 (0) 47.1 (8) 17.6 (3) 11.8(2) 23.5(4) 17 8.9 
Cardiologist 26.5 (9) 50 (17) 14.7 (5) 2.9 (1) 5.9 (2) 34* 17.8 
Pulmonologist  23.6(13) 49.1(27) 21.8(12) 1.8 (1) 3.6 (2) 55* 28.8 
Physical 
therapist a 
4 (1) 44 (11) 20 (5) 4 (1) 28 (7) 25 13.1 
* Totals do not equal those in Table 6 above because respondent did not give child’s date of birth.  
a therapist seen outside of school 
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Figure 9: Respondents who felt their child does not need the service of healthcare providers 
 
5.1.5 Durable Medical Equipment and Devices    
About 46 to 61% (n=83 to 111) of children had used power wheelchair, manual wheelchair 
and/or night splints while much less used lung clearance and assisted ventilation devices (Table 
8).  The percentage of children in each age category using selected durable medical equipment is 
shown in Table 9. A large jump in percentages occurred between the 6 to 9 and 10 to 13 age 
groups for both wheelchair types. All individuals with DMD aged 18 and older were using a 
power wheelchair while 55 to 58% (n=18 to 19) were using respiratory devices. In this table, 
data are shown for those who responded both to child’s age at the time of survey and to use of 
equipment questions. 
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Table 8: Equipment and breathing device use 
Device* 
 Count 
(Yes) 
Total 
Response a 
Percentage 
(Yes/Total 
Response) 
Night splints 111 183 60.6 
Manual wheelchair 94 182 51.6 
Power wheelchair 83 180 46.1 
Lung clearance devices b 33 179 18.4 
Assisted ventilation devices c 28 179 15.6 
* Respondents were asked “Has your child used the following? (Yes/No)” 
a Total response from 191 possible respondents 
b Respondents who selected at least one lung clearance device from 5 types (Emerson 
cough assist, Vortran percussive nebulizer, intrapulmonary percussive ventilation, Thera 
vest, chest percussion) 
c Respondents who selected at least one assisted ventilation device from 6 types (Bi-PAP, 
tracheotomy, C-PAP, mouthpiece/Sip n Puff, cuirass, negative pressure) 
 
Table 9: Percentage of children in age category who have used equipment or device 
Equipment/Device 
% (n) of total children in age category who have used device*  
1 to 5 
(n=34) 
6 to 9 
(n=57) 
10 to 13 
(n=38) 
14 to 17 
(n=27) 
≥ 18 
(n=33) 
Total 
Count 
for 
device 
Night splints 23.5 (8) 71.9 (41) 57.9(22) 77.8 (21) 54.5 (18) 110 
Manual wheelchair 2.9 (1) 29.8 (17) 71.1 (27) 85.2 (23) 78.8 (26) 94 
Power wheelchair 0.0 (0) 8.8 (5) 57.9 (22) 85.2 (23) 100 (33) 83 
Lung clearance devices a 2.9 (1)  3.5 (2)  2.6 (1)  37.0 (10)  54.5 (18) 32 
Assisted ventilation devices b 0.0 (0) 1.8 (1) 2.6 (1) 25.9 (7) 57.6 (19) 28 
* Shown are those who selected “Yes” to use of equipment type (n varied) and gave their child’s age at the time of  
survey (n=189). Percentages were calculated using the total “Yes” responses for an age category divided by the total 
number of children from the survey in the age category. 
a as above for b in Table 8 
b as above for c in Table 8 
5.1.6 DMD’s Impact: Worry, Limitations and Satisfaction 
Respondents were asked several questions about the impact that aspects of DMD had on them or 
their child in the month before completing the survey. One such question asked how much 
emotional worry or concern did their child’s physical health, emotional well-being and behavior 
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 caused them with “None”, “A little bit”, “Some”, “Quite a bit” and “A lot” as possible answers. 
To aid in analysis, these questions were collapsed into three categories with “None” as its own 
category; “A little bit” and “Some” combined into a second category and “Quite a bit” and “A 
lot” combined into a third category. About 44% , 38% and 22% of respondents reported quite a 
bit or a lot of worry or concern for their child’s physical health, emotional well-being  and 
behavior, respectively (Figure 10). 
Limitations in the child’s schoolwork or activities with friends due to problems with 
health, emotional difficulties and behavioral difficulties in the past month were rated by 
respondents with “No, not limited”, “Somewhat limited” and “Yes, very limited” answers.  
(Figure 11). The majority of parents did not report that their child experienced limitations due to 
health, emotional, or behavioral difficulties in the past month. 
Lastly, respondents rated how satisfied they thought their child felt about life overall in 
the past month with “Very satisfied”, “Somewhat satisfied”, “Not satisfied/Not dissatisfied”, 
“Somewhat dissatisfied” and “Very dissatisfied” as answer options. About 80% (n=149) of 
respondents thought their child felt very satisfied or somewhat satisfied with life in the past 
month  (Figure 12). 
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 Figure 10: Respondent worry or concern for child's physical, emotional and behavioral health in past month 
 
Figure 11: Child's limitations due to physical, emotional and behavioral difficulties 
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Figure 12: Child's overall life satisfaction in past month 
 
5.2 DIFFERENCES BETWEEN PAPER AND INTERNET NIFD POPULATIONS 
Because the NIFD population was composed of two populations (one who took the survey in 
paper format and the other who took a web-based survey posted on the Internet) analysis for 
significant differences between population demographics was performed. Based on the 
differences uncovered, selected variables were analyzed between these populations. 
39.1% 
41.8% 
8.7% 
9.2% 
1.1% 
Child's overall life satisfaction in past month (n=184) 
Very satisfied (72)
Somewhat satisfied (77)
Not satisfied / Not dissatisfied (16)
Somewhat dissatisfied (17)
Very dissatisfied (2)
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 5.2.1 Demographic Factors 
Demographic factors were significantly different between the two populations for child’s age, 
combined age of parents/guardians, highest parent/guardian education level, and annual family 
income (Table 10).  
 The mean age of the parents/guardians and age of the child among the Internet 
respondents was lower than that of the Paper respondents. For the Internet population, child ages 
ranged from 1 to 20 years and mean parent/guardian ages ranged from 24 to 58 years. For the 
Paper population, child ages ranged from 2 to 28 years and 20 to 66 years for parent/guardian 
ages.   The percentage of parents/guardians aged 40 and over was 63.1% (142 of 225 responses) 
for the Paper population versus 49.3% (66 of 134 responses) for the Internet population. For 
child’s age, 51.7% (61 of 118 responses) of the Paper population were aged 12 and over versus 
28.2% (20 of 71 responses) of the Internet population. Both of these differences were significant 
by Fisher’s 2-sided exact test at p = 0.011 for parents’ age and p = 0.002 for child’s age.  
 The highest level education level achieved between parent/guardian pairs was higher in 
the Internet population with about 61% (n=43) having a bachelor’s degree or higher versus 39% 
(n=46) achieving this level in the Paper population. Annual income was also higher in the 
Internet population with 80% (n=56) have annual incomes equal to or greater than $50,000 
versus 67% of the Paper population with this income level. 
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 Table 10: Demographic differences between Paper and Internet populations 
Demographic Factor 
Population 
P-value 
Paper      Paper 
response   
(of n=119) 
Internet  Internet 
response 
(of n=72) 
Relationship to child:  
Biological Mother % (n) 
80 (92) 115 79.2 (57) 72 1.0 c 
Parent/Guardian Ages mean in years 
± SD 
43.3±8.9 225* 40.4±7.2 134* 0.001d 
Highest parent/guardian education 
level a: ≥ Bachelor’s degree % (n) 
39.3 (46) 117 61.4 (43) 70 0.004c 
Employment b: Two full-time 
working parent/guardians %(n) 
42.7 (50) 117 44.1 (30) 68 0.879c 
Annual income: ≥$50,000 %(n) 61.7 (71) 115 80 (56) 70 0.009 c 
Child Age: mean in years ± SD   12.6±6.4 118 8.8±4.5 71 <0.001d 
Child glucocorticoid use % (n) 71.4 (85) 119 66.1 (39) 59 0.492c 
Child’s Race:White/Caucasian %(n) 92.2 (107) 116 97.1 (66) 68 0.217c 
Child’s Ethnicity:Not Hispanic %(n) 96.5 (110) 114 94.4 (67) 71 0.485c 
* Respondents were able to enter values for two parents or guardians; total possible n for Paper = 238 and n for 
Internet = 144 
SD = standard deviation 
a Parent education was determined by counting the highest education level between parent/guardian pairs (or 
education level of single responses in the case that a second education level for a second parent/guardian was not 
given) for each represented child. 
b Categories for family employment status were generated from combinations of three possible responses (full-
time, part-time, not working) for two parents/guardians (e.g. 2 full-time workers;1 full-time + 1 part-time; etc.). 
c Fisher’s exact 2-sided test; values in bold are significant at alpha ≤ 0.05 
d Independent samples t-test; values in bold are significant at alpha ≤ 0.05 
5.2.2 Other Variables 
Given these demographic differences, the distributions of other survey variables were compared 
between populations. Variables examined were: independent walking; one or more other 
diagnoses; insurance plans; one or more non-covered medical expense; quality of healthcare 
since diagnosis; respondent understanding of DMD; seeing a neurologist, cardiologist, 
pulmonologist, physical therapist; use of night splints, manual & power wheelchairs, lung 
clearance devices, assisted ventilation devices; child’s overall life satisfaction and limitations due 
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 to health problems. To facilitate testing for significant difference between variables, some 
modifications were made to variable categories as described in Methods.  
 Five variables with significant differences between populations were found (Table 11).  
Ability to walk independently was less in the Paper population, which also had higher use of 
power wheelchair and assisted ventilation devices.  Higher percentages of the Internet population 
saw a neurologist and physical therapist outside of school. 
 
Table 11: Significant differences in ambulation and healthcare variables between Internet and Paper 
populations 
Variable 
Population 
P-value a 
Paper     
% (n) 
Paper 
response   
(of n=119) 
Internet 
% (n) 
Internet 
response 
(of n=72) 
Walking independently 45.8 (54) 118 76.1 (54) 71 <0.001 
Seeing a neurologist 77.8 (91) 117 96.9 (63) 65 <0.001 
Seeing a physical therapist b 40.7 (48) 118 66.7 (42) 63 0.001 
Power wheelchair 53.8 (64) 119 31.1 (19) 61 0.005 
Assisted ventilation devices 19.3 (23) 119 8.3 (5) 60 0.08c 
a Fisher’s exact 2-sided test; values in bold are significant at alpha ≤ 0.05 
b physical therapist seen outside of school 
c Fisher’s exact 2-sided test; this variable was significant at p=0.041 for a one-sided Fisher’s exact test 
 
5.3 ASSOCIATIONS BETWEEN NIFD VARIABLES 
To examine associations between survey variables, correlations were identified and used to 
generate a regression model. Correlations were observed between increasing child age and 
decreased independent ambulation, use of wheelchairs and respiratory devices and seeing a 
cardiologist or pulmonologist. Regression analysis was performed to explore predictors for 
outcomes of pain and overall life satisfaction. 
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 5.3.1 Regression Analysis 
A partial correlation table identified significant associations between selected variables while 
controlling for survey population. This table was used to reveal overall associations among 
dataset variables and to identify independent variables to include in linear regression modeling 
for selected dependent variables. Forward and backward linear regression modeling was 
generated for child’s frequency of bodily pain or discomfort in the past month for the Paper 
population only (Table 12) and for child’s satisfaction with life overall in the past month for the 
total NIFD population (Table 13) using all significantly associated variables from the partial 
correlation table. The strongest predictors of bodily pain or discomfort were use of albuterol for 
strength (beta 0.28) and limitations due to health problems (beta 0.23). The strongest predictors 
of child’s overall life satisfaction were child’s satisfaction with friendships (beta 0.53) and 
child’s health other than DMD (beta 0.23). 
 
Table 12: Regression predicting frequency of bodily pain or discomfort in the Paper population* 
Model Adjusted R2 : 0.438   
Variable a Standardized coefficients Beta Significance 
Use of albuterol for strength 0.281 0.001 
Limitations due to health problems 0.229 0.01 
Child’s satisfaction with school ability 0.196 0.02 
Use of manual wheelchair 0.182 0.04 
Seeing a cardiologist 0.148 0.07 
Use of proton pump inhibitors 0.143 0.08 
* Respondents’ rating of child’s frequency of bodily pain or discomfort in the past month was coded from 0 to 4, 
starting with “Never” and going to “Every day or almost every day” 
a Limitations due to health problems and Child’s satisfaction with school ability were coded similarly in that 
limitations and dissatisfaction increased going from 0 or 1 to higher numbers; Albuterol, manual wheelchair, 
cardiologist and proton pump inhibitors were all coded with 0 = No and 1 = Yes 
 
 
 51 
 Table 13: Regression predicting frequency of child's overall life satisfaction in Internet and Paper 
populations* 
Model Adjusted R2 : 0.531   
Variable a Standardized coefficients Beta Significance 
Child’s satisfaction with friendships 0.531 <.001 
Child’s health other than DMD  0.233 <.001 
Use of medications for ADD/ADHD 0.179 0.001 
Walking independently -0.154 0.01 
Respondent worry for child’s behavior 0.119 0.05 
* Respondents’ rating of child’s overall life satisfaction in the past month was coded from 1 to 5, starting 
with “Very satisfied” and going to “Very dissatisfied”. 
a Child’s satisfaction with friendships used the same coding as overall life satisfaction; Child’s health 
other than DMD and Respondent worry for child’s behavior were coded similarly in that health quality 
worsened and worry increased going from 0 or 1 to higher numbers; ADD/ADHD medications and 
Walking independently were both coded with 0 = No and 1 = Yes.  
   Independent variable excluded by the model: Survey population (p = 0.51) 
 
5.4 COMPARISON OF NIFD DATA WITH DUCHENNECONNECT DATA 
Age and racial/ethnic background (Table 14) and use of glucocorticoids, walking ability and 
insurance plans (Table 15) for individuals diagnosed with DMD are compared between NIFD 
and DuchenneConnect (DC) populations. DuchenneConnect had higher mean ages of and lower 
percentages of Caucasian/non-Hispanic individuals with DMD. The NIFD population had a 
larger proportion with traditional insurance plans. More of the DC population was able to walk 
on their own without help than NIFD. Glucocorticoid use was not significantly different between 
the populations. 
 Other diagnoses, problems with medical expense coverage and use of selected services, 
equipment and devices are also compared in Table 16. The NIFD population reported higher 
numbers of co-occurring diagnoses; problems with coverage of devices/equipment and 
medicines; and use of night splints and power wheelchairs. The DC population reported higher 
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 use of therapies (physical, occupational, speech) and manual wheelchairs. Use of breathing 
devices was not significantly different between populations. 
 
Table 14: Demographics of individuals with DMD between NIFD and DuchenneConnect populations 
Variable       
[p-value]  
Population  
NIFD DuchenneConnect 
Age, mean±SD 
(range)  
[p < 0.001a] 
 
11.2 years ±6.1 (1 to 28) 13.1±6.8 (1 to 40) b 
Age Categories, 
range in years (n)  
 
  
Race/Ethnic 
background (n) 
 
 
White/Caucasian
+ Not Hispanic: 
[p = 0.0002c] 
  
SD = standard deviation 
a Independent samples t-test; values in bold are significant at alpha ≤ 0.05 level  
b Excludes 23 respondents who said current ages was >40 years. See Methods. 
c Fisher’s exact 2-sided test by using the shown category to make the data into a dichotomous variable; values in 
bold are significant at alpha ≤ 0.05 level 
* “Other” was an option on the Internet but not Paper version of NIFD 
  
 
 
18.0% 
30.2% 
20.1% 
14.3% 
17.5% 
n=189 
1 to 5 (34)
6 to 9 (57)
10 to 13 (38)
14 to 17 (27)
≥18 years 
(33) 
8.8% 
24.6% 
25.3% 
20.3% 
21.1% 
n=1148 
1 to 5 (101)
6 to 9 (282)
10 to 13 (290)
14 to 17 (233)
≥18 years (242) 
91.1% 
2.8% 
3.3% 
2.2% 
0.6% 
n=180 
White/Caucasian +
Not Hispanic (164)
White/Caucasian +
Hispanic (5)
Asian/Pacific
Islander (6)
Other* (0)
Black/African
American (4)
80.1% 
9.8% 
5.0% 
2.6% 1.4% 1.0% 
n=1182 
White/Caucasian +
Not Hispanic (947)
White/Caucasian +
Hispanic (116)
Asian/Pacific
Islander (59)
Other (31)
Black +/- African
American (17)
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 Table 15: Insurance, glucocorticoid use and walking ability between NIFD and DuchenneConnect 
populations 
Variable       
[p-value]  
Population  
NIFD DuchenneConnect 
Insurance 
plans* (n) 
 
Traditional 
insurance 
plans: 
[0.033 a] 
  
Gluco- 
corticoid 
Use b (n) 
 
 
[0.320a] 
  
Walking 
ability c (n) 
 
Walk 
without 
help: 
[<0.001a] 
  *Insurance: Respondents could select all plans that applied; shown are the percentages of counts out of total pool of 
selections made by the respondents.  
a Fisher’s exact 2-sided test by using the shown category to make the data into a dichotomous variable; values in 
bold are significant at alpha ≤ 0.05 level 
b Indicates those who have used glucocorticoids in the past or currently; excluded non-response from NIFD and 
“Don’t know” responses from DC total response counts 
 c See Methods for data harmonization 
 
 
 
28.8% 
64.8% 
2.6% 1.7% 2.1% 
n=235 selections 
Medicaid/Medicare/Sta
te program (67)
Traditional insurance
plans (151)
Other (6)
Military (4)
No insurance (5)
31.5% 
56.6% 
8.4% 
2.4% 1.2% 
n=1146 selections  
Medicaid/Medicare/State
program (455)
Traditional insurance
plans (819)
Other (121)
Military (34)
No insurance (17)
30.3% 
69.7% 
n=178 
No Corticosteroids
(54)
Corticosteroids
Used (124)
26.7% 
73.3% 
n=1178 
No
Corticosteroids
(314)
Corticosteroids
Used (864)
8.9% 
39.8% 47.6% 
3.7% 
n=191 
Walk on own
without help (17)
Walk on  own but
need help (76)
Use a wheelchair  &
rarely/never walk
(91)
Unknown (7)
47.2% 
11.6% 
41.0% 
0.2% 
n=1201 
Walk on own without
help (567)
Walk on  own but need
help (139)
Use a wheelchair  &
rarely/never walk (493)
Unknown (2)
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 Table 16: Comparison of other variables in common between NIFD and DuchenneConnect populations 
Variables Key 
Other 
Diagnoses 
 
Problems 
with coverage 
for medical 
expenses 
 
39.8 
30.9 
15.2 
5.8 5.2 3.7 
1 3 
11.1 
3 
0.9 1.7 0.4 0.6 
0
5
10
15
20
25
30
35
40
Pe
rc
en
ta
ge
 (o
f t
ot
al
 r
es
pe
ct
iv
e 
po
pu
la
tio
n)
 
24.1 
11.5 
3.2 
6.3 
0
5
10
15
20
25
Devices or equipment*** Medications**
Pe
rc
en
ta
ge
 (o
f t
ot
al
 r
es
pe
ct
iv
e 
po
pu
la
tio
n)
 
*     p ≤0.05         
**   p ≤0.01         
*** p ≤ 0.001 
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 Therapies 
 
Use of Night 
Splints and 
Wheelchair 
 
Use of 
Breathing 
Devices  
 
(no significant 
differences) 
 
DD = Developmental delay; ADD/ADHD = Attention deficit; Vision/Hearing = Impairment; MR = Mental 
retardation; PDD = Pervasive developmental disorder; Bi-PAP = bi-level positive airway pressure; C-PAP = 
continues positive airway pressure 
 
47.1 
23.6 
7.9 
59.6 
40 
31.5 
0
10
20
30
40
50
60
Physical** Occupational*** Speech***
Pe
rc
en
ta
ge
 (o
f t
ot
al
 r
es
pe
ct
iv
e 
po
pu
la
tio
n)
 
58.1 
13.6 
43.4 
33.7 
20.1 
31.2 
0
10
20
30
40
50
60
Night splints*** Manual Wheelchair* Power Wheelchair**
Pe
rc
en
ta
ge
 (o
f t
ot
al
 r
es
pe
ct
iv
e 
po
pu
la
tio
n)
 
21.2 
11 10.5 
1.6 0.5 
19.4 
10.3 
11.5 
2 1.5 
0
5
10
15
20
25
Any breathing
device(s)
Cough Assist Bi-PAP Tracheostomy C-PAP
Pe
rc
en
ta
ge
 (o
f t
ot
al
 r
es
pe
ct
iv
e 
po
pu
la
tio
n)
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 6.0  DISCUSSION 
6.1 CHARACTERIZATION OF THE NIFD DATASET 
6.1.1 Demographics 
Most respondents (almost 80%) were biological mothers, which may imply their role as primary 
caregivers among families with DMD. The respondent group included families at all stages of 
DMD from pre-symptomatic to late non-ambulatory, reflected by the average age of both parents 
and/or guardians being 42 years ± 8.5 with an age range spanning ages 20 to 66 and the average 
age of the child being 11.2 years ± 6.1 with an age range spanning ages 1 to 28 years. About 
30% of children fell in the 6 to 9 year old group and about 20% in the 10 to 13 year old group. 
Almost 70% of respondents reported that their child has used glucocorticoids, showing this 
intervention’s role as a standard part of DMD care. 
The parents/guardians of the children were well educated with about 59% obtaining at 
least some college to a graduate or professional degree. This was similar to the education 
attainment of the US population over 25 years and older (55%) during the NIFD survey period 
(Census 2012). Most (71%) parents/guardians were working full-time. Of those not working full-
time, roughly 13% worked part-time while 16% were not working at all. About half (51%) of 
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 families represented in this study had annual incomes of over $75,000. The median US 
household income around this time was just over $50,000 (DeNavas-Walt et al. 2012). 
6.1.2 Health Status of Child with DMD 
As would be expected given the age ranges of children from the survey, a wide range of walking 
ability was observed. About 57% of children were able to walk independently. Their ability in 
this regard varied, from being able to walk, run and climb without any difficulty or assistance to 
walking household distances only with slow progress. About 38% of children could not take any 
steps and primarily used a power or manual wheelchair.  
Pain or body discomfort during the past month was reported at varying frequencies for 
about 75% of children from the Paper population with almost 33% experiencing it every day or 
almost every day. This was comparable to 70% of parents who reported bodily pain in their child 
with DMD in a study by Zebracki et al that included males aged 8 to 18 years with a mean age of 
13.9 years (versus NIFD’s mean age of 11.2 years) (Zebracki and Drotar 2008). Zebracki et al’s 
study suggested that while pain occurs commonly in DMD, it is likely under-recognized by 
physicians, who reported less intensity of pain than their patients and patients’ parents did, and 
that regular pain assessment should be implemented in patient care. A study of adult men with 
DMD found almost 39% reported daily pain and 31% weekly or monthly pain (Rahbek et al. 
2005).  Pain management was briefly addressed in the DMD care recommendations with 
recognition of the variation in pain intensity experienced by patients and the need for more 
research addressing effective interventions throughout the disease course. More attention on 
palliative care (which addresses pain among other aspects of care) was suggested as an area that 
should have been discussed more in the DMD care recommendations (Cohn 2010). 
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 The majority of respondents felt their child’s health other than DMD was either excellent 
(31%) or very good (45%), a high rating of health though the question did not query what 
respondents interpreted as health other than DMD.  
Neurocognitive and behavioral conditions have been reported at higher incidences in 
DMD when compared to the general population. A study of about 350 Dutch and US individuals 
with DMD found an overall frequency of about 16% for neuropsychiatric disorders in those with 
DMD (Hendriksen and Vles 2008). In particular, 11.7% had received a diagnosis of ADHD and 
about 3% of autism spectrum disorder (ASD). These numbers were lower but similar to those 
found in the NIFD population, which had 15.6% and 6%, respectively, diagnosed with these two 
conditions. Other smaller studies found a similar prevalence of ASD to NIFD at about 4 to 5% in 
boys with DMD (Wu et al. 2005; Darke et al. 2006). Hendricksen et al noted that 
neuropsychiatric disorders can be over or under diagnosed depending on the physician, which 
could explain some of the variation between study populations (Hendriksen and Vles 2008).  
Language delays and verbal deficits have also been noted in boys with DMD (Hinton et 
al. 2001; Cyrulnik et al. 2007) and were reported to be diagnosed in about 30% of children in the 
NIFD population. Varying ranges of mental retardation (e.g. 19 to 35%) have been reported in 
boys with DMD (Cotton et al. 2001; Nereo et al. 2003). Children in the NIFD population were 
reported to have a lower diagnosis of mental retardation at a little over 5%. Several reports have 
noted that, despite a mean IQ one standard deviation below the population mean observed in 
DMD, there is wide variability in intellectual ability in DMD with most having normal 
intelligence (McDonald et al. 1995; Cotton et al. 2001; Hinton et al. 2001; Poysky 2007). 
Though not directly analyzed in the present study, co-occurring ADD/ADHD, ASD, 
mental retardation and delays likely increase the use of services such as mental health 
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 professionals and of medications for treatment. It is also possible that co-occurrence of other 
diagnoses has an impact on child’s abilities and life quality as was shown in a national survey of 
children with Fragile X (Bailey et al. 2008). In the present study, use of ADD/ADHD 
medications was associated with decreases in child’s overall life satisfaction.  
6.1.3 General Healthcare Coverage, Understanding and Quality 
Traditional insurance plans, managed care plans and state-sponsored plans such as Medicaid 
were the most commonly selected plan types among NIFD respondents. 44% of respondents 
indicated that at least one major medical expense was not covered by their health insurance plan. 
Durable medical equipment and therapies (PT, OT, Speech) were the most often selected non-
covered expenses at about 38% and 33%, respectively. The latter finding was consistent with 
respondents who gave concerns about expense or medical insurance as reasons why their child 
does not see a physical therapist outside of school. This was also consistent with write-in 
comments from respondents regarding difficulty in obtaining equipment and therapies (Appendix 
C.3.2).  
Almost 61% of respondents felt they understood the inheritance and services needed for 
DMD very well while 34% felt they understood somewhat well. Respondents’ actual 
understanding of what those services are were not queried and it is likely that parents may have 
had gaps in knowledge, especially in light of the lack of published DMD care recommendations 
at the time of survey. Correlation analysis did not reveal any significant associations between 
respondents’ understanding of DMD and demographic, impact and use of service, equipment or 
medication variables.   Parents of children with DMD often serve as advocates for their child, 
which often requires a good understanding of services and therapies their child needs. This need 
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 for understanding the complexities of care was reflected in some write-in comments from 
respondents regarding quality of healthcare (Appendix C.3.2). For instance, one respondent 
wrote, “[We] had to find items of interest relating to DMD and approach the doctor with them”. 
Another said, “His care is high-quality because I search out the best doctors in the area versed in 
DMD”. 
Over 50% of respondents felt their child had received high quality healthcare since the 
DMD diagnosis while about 35% felt they had received adequate care. The remainder felt they 
had either varied or less than adequate healthcare. Lack of coverage for major expenses reported 
by 44% of respondents is a potential factor in perception of healthcare quality though a 
significant correlation was not observed between these variables. Issues related to healthcare 
quality raised in write-in comments about healthcare (Appendix C.3.2) included clinic logistics, 
doctors’ approaches to care and barriers to needed services/equipment. Correlation analysis did 
not reveal any significant associations between quality of healthcare since diagnosis and 
demographic, impact and use of service, equipment or medication variables.  
6.1.4 Healthcare Providers 
A multidisciplinary approach was suggested as the neurologist and cardiologist represented the 
providers that the highest percentage of children saw at about 85 and 71% respectively. Roughly 
half of children saw a pulmonologist or a physical therapist outside of school. In a study of 34 
U.S. males with DMD aged 12 to 34 years between 2005-2006, almost 70% had received 
respiratory care (Arias et al. 2011), which could be higher than NIFD due to an older study 
population and the term “respiratory care” encompassing more than seeing a pulmonologist. 
About 61% of NIFD respondents had seen a genetic counselor or geneticist as determined from a 
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 different section of the survey. The higher use of these providers is consistent with their key 
roles in diagnosis and management of DMD. Further factors related to use of four of these 
providers are discussed below.  
 The mean ages at first visit for the top four providers seen (neurologist, cardiologist, 
pulmonologist, physical therapist) were calculated for the Paper population. The average age for 
first visit to the neurologist fell within expected ages of diagnosis at an average age of 5 years 
(SD ± 3). Similarly, age at first visit to a physical therapist 6 years (SD ± 3) was close to typical 
ages of diagnosis and appropriate initiation of preventive interventions prior to ambulation loss. 
The mean age at first visit for the cardiologist was 9 years (SD ± 5) reflecting that the 2005 
American Academy of Pediatricians (AAP) cardiac recommendation of evaluation at diagnosis 
(and the DMD care recommendations’ guideline at diagnosis or by six years of age at the latest) 
were not followed by all families (AAP 2005). Similarly, the mean age at first pulmonologist 
visit was 11 years (SD ± 5) compared to the 2004 American Thoracic Society (ATS) respiratory 
consensus statement (also adopted by the DMD care recommendations) recommending an early 
stage visit (ages 4 to 6) and before permanent wheelchair usage for baseline evaluations (Finder 
et al. 2004). Twice yearly visits are recommended a) after confinement to wheelchair, b) at less 
than 80% predicted forced vital capacity level and/or c) at age 12 years—thus the children in the 
NIFD population likely made their first visit around this stage of disease.  
Reasons why children did not see the top four providers were explored. For the 
neurologist, cardiologist and pulmonologist, the largest majority of respondents felt that the child 
did not need the services of these providers. These respondents represented about 9%, 18% and 
29% of the total survey population for each provider, respectively. All (for the neurologist) or 
roughly three-quarters (for the cardiologist and pulmonologist) of the children these respondents 
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 represented were aged 6 or older, key ages for seeing these providers. Expense and concern 
about medical insurance were not given as reasons for not seeing these providers by any 
respondents. Bothwell et al found that pulmonary services and physical therapy were viewed by 
parents as increasingly important services to be utilized in the future, as their child aged 
(Bothwell et al. 2002). Thus, it is possible that NIFD respondents, while being aware of the need 
for these services in the future, did not feel their child needed them at the present time. 
About 32% (n=25) of respondents giving a reason why their child does not see a physical 
therapist also gave the reason of not needing the service (13% of the total survey population). 
This was the most selected reason for why children did not see a physical therapist. With the 
exception of one child, these children were all aged 6 years and older. The selection of other 
reasons why the child did not see a physical therapist was more varied than the other providers, 
however. Availability, expense and concern for medical insurance were equally given as reasons 
for not seeing a physical therapist. This agrees with respondents’ selection of therapies 
(including PT) as a top major expense not covered by health insurance plans. Additionally, these 
responses may reflect a diminished availability of physical therapists specialized in care of 
children with DMD.  
The remaining providers (nutritionist, physiatrist, occupational therapist, social worker, 
gastroenterologist, mental health therapist and speech therapist) were seen by about a quarter or 
less of NIFD respondents. Arias et al reported receipt of nutrition counseling and social services 
in roughly 40% and 35%, respectively, of 34 males with DMD (Arias et al. 2011). Mental health 
services were received by about 25%. NIFD respondents reported their child saw nutritionists, 
social workers and mental health therapists less at 27%, 23% and 16%, respectively. 
Interestingly, over 30% of NIFD respondents reported their child being diagnosed with a speech 
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 delay but only 8.5% reported seeing a speech therapist outside of school. It may be that their 
child received speech therapy through school. 
 Additionally, the predominant reason given for why children did not see the other seven 
providers (nutritionist, physiatrist, occupational therapist, social worker, gastroenterologist, 
mental health therapist and speech therapist) was also that the respondent felt their child did not 
need their services (Table C21). It is quite possible these providers were not a part of the child’s 
healthcare team and were therefore deemed to not be needed by the child. Or, an outside referral 
for such services may have been forgotten or put on low priority by families given the myriad 
appointments often needed for a child with special needs. Additionally, age likely plays a factor 
in why respondents feel a service is not needed, as some services may be perceived to be needed 
at later stages, though the child does not currently use the service. In a small study, Bothwell et 
al examined families’ perceptions of services in DMD (Bothwell et al. 2002). They found that 
services involving ambulation prolongation were most important, particularly for parents of 
younger boys. In families with older boys, mental health issues became more important to 
parents. 
Overall, the perception of a child not needing a service may reflect respondents’ lack of 
awareness of the provider’s role or importance in their child’s care. This emphasizes the need for 
these specialties to be represented on a child’s healthcare team (or at least readily accessible 
outside of the care team) and for increased awareness of and education on DMD care 
recommendations. Genetic counselors are poised to serve in an on-going educator role for 
families as genetic counselors are often present at diagnosis and may serve in care coordination 
roles. Assisting with distribution of DMD care recommendations, following up with subsequent 
 64 
 family questions and visiting aspects of care that may need to be re-emphasized or initiated are 
areas where genetic counselors can assist.  
6.1.5 Durable Medical Equipment and Devices 
Several pieces of equipment and devices are recommended for maintaining mobility and 
independence as well as respiratory function in DMD.  About 60% of respondents reported that 
their child has used night splints (ankle-foot orthotics), which are indicated for prevention or 
reducing the progression of contractures through all stages of DMD. Varying percentages of 
children in each age category reportedly used night splints with the biggest jump in use occurring 
between the 1 to 5 (24%) and 6 to 9 (72%) age groups, reflecting initiation of this therapy in the 
older group.  
Manual and power wheelchair usage increased with age as would be expected. A large 
jump occurred between the 6 to 9 and 10 to 13 age groups for both wheelchair types, reflecting 
the typical ages of ambulation loss. The practice of the initial use of a manual wheelchair 
followed by use of a power wheelchair was suggested by the higher use of the manual chair in 
the 6 to 9 and 10 to 13 age group compared to the same or greater use of the power chair in the 
14 to 17 and 18 and older age groups. Power wheelchair transition is recommended early when 
the ability to walk community distances decreases (Bushby et al. 2010b). The NIFD usage of 
wheelchairs was similar to the Muscular Dystrophy Surveillance Tracking and Research 
Network’s 2007 report of wheelchair usage in males 5 to 24 in four US states (Romitti et al. 
2009). 
Respiratory devices are a critical aspect of care, particularly in advanced stages of the 
DMD. Use of lung clearance devices is indicated to prevent collapse and infection of the lungs 
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 (Finder et al. 2004). About 18% of respondents reported that their child used at least one of five 
devices, including the Emerson Cough Assist device. These children represented 37% of 14 to 17 
years olds and about 55% of those 18 years and older. As respiratory function decreases, assisted 
ventilation becomes increasingly important. About 15% of children have used at least one of six 
devices representing about a quarter of 14 to 17 years old and about 58% of those 18 years and 
older. About 81% of the former and 91% of the latter age groups saw a pulmonologist, meaning 
there were almost 10 to 20% of individuals in these age groups who could benefit from specialty 
respiratory care. Respondents and their children in this group could have been unaware of 
changes in respiratory function as declines in lung function can occur silently without the 
awareness of an individual with DMD. This even further points to the importance of preventive 
respiratory care. It is also possible these individuals were receiving respiratory monitoring or  
care through other healthcare providers without seeing a pulmonologist. 
6.1.6 DMD’s Impact: Worry, Limitations and Satisfaction 
The progressive nature of DMD can have a serious impact on a child or adult’s physical, 
emotional and behavioral health. Respondents’ were asked to select the amount of worry or 
concern they had experienced in the past month for these three dimensions of their child’s health. 
Almost all respondents replied to these questions (n=190). When compared side-by-side, the 
responses showed an increasing amount of worry or concern going from behavioral to emotional 
to physical health with about 22%, 38% and 44%, respectively, selecting “Quite a bit” or “A lot”. 
These results agree with a study of mothers with a child with DMD which found that behavioral 
and physical aspects of DMD contributed to maternal stress (Nereo et al. 2003). Parental 
perception and adjustment to different aspects of health changes throughout the life of their child 
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 with DMD (Abi Daoud et al. 2004; Poysky and Kinnett 2009; Samson et al. 2009) thus levels of 
worry or concern are also likely to vary by and become intensified at certain stages of disease. 
Chen et al found that parental health and stress levels were associated with parental perceptions 
of their child’s health status rather than their child’s actual health status (Chen and Clark 2010). 
Respondents in the NIFD study, however, indicated they worried more about emotional, 
behavioral, and physical domains than they perceived limitations for their children in these areas, 
though the actual limitation statuses of the children were not determined and could have been 
lower than reported.  
 In helping parents with their worries, concerns, and overall adjustment, several 
recommendations have been made for care providers. Chen et al suggest one way to help 
parental health and coping is to involve them in their child’s care plan and encourage shared 
decision making. Other recommendations include teaching parents strategies, such as emotion 
coaching, to help children through emotional problems; use of a care coordinator for each 
family; eliciting family feedback on satisfaction with care; addressing parental concerns and 
questions; and maintaining good ties between clinic and advocacy groups (Nereo et al. 2003; 
Poysky 2007; Poysky and Kinnett 2009) 
 Respondents’ reporting of their child’s limitations in schoolwork or activities with friends 
in the past month somewhat mirrored parental worry or concern in that the reasons why children 
were somewhat or very limited increased going from behavioral difficulties to emotional 
difficulties and lastly to problems with health (15.7%, 15.6%, 26%, respectively). In contrast to 
the respondents’ worry or concern, however, the majority of respondents (74 to 84%) felt their 
children were not limited in these activities by these domains. Thus, reasons other than current 
limitations in social or school activities contributed to respondents’ higher rates of worry/concern 
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 in these domains. These worries could be related to future limitations that respondents foresaw 
for their child. Additionally, the response rates for the limitations questions were lower, 
however, with 172 to 173 responses (of a possible 191) so it is possible that more limitations 
were experienced by children but were not reported.  
 One study found that 26% of boys with DMD had clinically significant social problems 
as rated by their parents; age and wheelchair use did not significantly add to the report of 
behavioral problems (Hinton et al. 2006). Another study of parent-reported psychosocial 
adjustment in boys with DMD found that while most boys adjusted well, about 17% of boys 
were at risk for psychosocial problems (Hendriksen et al. 2009). This is similar to the 16% of 
NIFD respondents who reported some level of limitations due to emotional and/or behavior 
problems. Because boys with DMD are at increased risk for behavioral problems, both due to the 
physiological effects of DMD and secondary to disease progression, on-going evaluation is 
recommended (Polakoff et al. 1998; Poysky 2007; Bushby et al. 2010a). Parents of children with 
activity limitations were found to be at higher risk for poor physical and mental health, 
underscoring the impact that DMD can have on the entire family (Witt et al. 2009).   
Respondents rated what they perceived their child’s overall life satisfaction was during 
the past month. Of 175 respondents, most felt their child was either very (39%) or somewhat 
satisfied (42%). Roughly 10% felt their child was somewhat or very dissatisfied. Multiple studies 
have shown high quality of life or life satisfaction levels in individuals with DMD (Kohler et al. 
2005; Rahbek et al. 2005; Baiardini et al. 2011; Simon et al. 2011). Conversely, some self-
reported and parent-proxy studies have found some or all health-related quality of life measures 
assessed to be lower than controls in the DMD population (Grootenhuis et al. 2007; Bray et al. 
2010; McDonald et al. 2010). Differences in geography, healthcare systems, survey instrument, 
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 study sample size as well as the subjective nature of satisfaction and quality of life domains are 
some of the likely factors responsible for such variation. In addition, standard quality of life 
instruments have been suggested to emphasize clinical aspects of disease and physical 
functioning (Simon et al. 2011). Though NIFD used proxy measure of child’s life satisfaction, 
the high percentage of respondents who said their child was satisfied agrees with the former set 
of studies. A thematic study of interviews with nine teenagers with DMD found that most viewed 
themselves as “as adolescents who just happen to also have chronic disease” and were not in 
crisis regarding their condition (Pehler and Craft-Rosenberg 2009). These studies emphasize the 
importance of healthcare providers not making assumptions about a patient’s quality of life or 
life satisfaction, particularly since providers tend to underestimate these aspects in patients (Bray 
et al. 2010). 
Recommendations for care providers to help adjustment in individuals with DMD (and 
perhaps to thereby increase life satisfaction) include providing patient-centered care and eliciting 
feedback on that care; assessing and providing support for mental health and educational needs; 
and promoting independence, educational opportunities and transition to adult care (Rahbek et al. 
2005; Poysky and Kinnett 2009; Bushby et al. 2010a) 
6.2 DIFFERENCES BETWEEN PAPER AND INTERNET NIFD POPULATIONS 
6.2.1 Demographic factors 
Significant demographic differences were found between the two populations, the Paper 
population taking the survey as a baseline evaluation in the CINRG DMD Natural History study 
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 and the Internet population taking the survey from clinic announcement and possibly by finding 
the survey via Internet search. These differences were found between child and parent/guardian 
ages, parent/guardian education level and annual family income. 
The Internet population had a younger mean child age of 8.8 years (range 1 to 20)  versus 
that of the Paper population’s 12.6 years (range 2 to 28). Expectedly, parent/guardian age also 
followed this trend with the Internet mean parent/guardian age of 40.4 years (range 24 to 58) 
versus 43.3 years (range 20 to 66). 
From a per family perspective, the Internet population had higher education levels when 
assessed by highest level attained between parent/guardian pairs. About 61% of the Internet 
population had at least one parent/guardian with a Bachelor’s degree or higher versus about 39% 
of the Paper population. The respective populations did not show significant differences between 
combinations of employment statuses of parents/guardians but did for annual family income. The 
Internet population had higher incomes than the Paper population with 80% versus 62%, 
respectively, having household incomes equal to or higher than $50,000.  
Taken together, there are a number of ways these differences could affect the family’s 
experiences. The younger parent age and higher education and income of the Internet population 
could reflect that this population’s familiarity with and better access to online resources. Parents 
from the Internet population may have been searching the web regarding their son’s diagnosis, 
care or DMD trials and came across the NIFD survey. It is also possible given their child’s 
younger age (and therefore closeness to initial diagnosis) that they were given (or better able to 
access) newly available resources on recommended care. Families from the Paper population had 
older children who therefore would be at more advanced stages of DMD. This may have affected 
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 annual income levels (which were lower in the Paper population) as a higher burden of expenses 
for care occurs as individuals with muscular dystrophy age (Ouyang et al. 2008).  
6.2.2 Other Variables 
Comparison between populations for key variables revealed five with significant differences: 
ability to walk independently, seeing a neurologist, seeing a physical therapist, use of power 
wheelchair and use of assisted ventilation devices. The p-value for assisted ventilation devices 
approached significance in the Fisher’s two-tailed test (p=0.08) and was significant by Fisher’s 
one-tailed test (p=0.04).  
 Interestingly, the Internet population had a higher proportion of children who saw a 
neurologist and who saw a physical therapist outside of school when compared to the Paper 
population. Higher use of these providers could reflect better referrals and/or understanding of 
these providers’ roles in care in the Internet population. The latter is supported by Bothwell et 
al’s finding that families who were closer to the age of diagnosis of DMD (i.e. likely who had 
younger children with DMD) placed increased importance on neurology, orthopedic services and 
occupational therapy than families whose child was diagnosed greater than 6 years prior 
(Bothwell et al. 2002). The difference in seeing a physical therapist could be due to better access 
to and/or ability to afford such services given that these were reasons given for why children did 
not see this provider and given the Internet population’s higher annual incomes. Lower parent 
education and income levels, both different between the Paper and Internet populations, were 
factors found to be associated with being less likely to have a medical home for children with 
muscular dystrophy (Ouyang et al. 2012). These factors could have affected use of the above 
providers in the Paper population if they lacked a centralized place to receive care as in the 
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 concept of a medical home.  It is curious that the Paper population reported lower use of a 
neurologist given their involvement in the CINRG DMD Natural History study whose site 
primary investigators were mostly neurologists. Paper respondents may not have recognized the 
term “Neurologist” on the questionnaire as the type of doctor at the CINRG site. Again, this 
points to the importance of families understanding who providers are on the healthcare team and 
what they do. 
 The higher use of power wheelchairs and assisted ventilation devices as well as the 
smaller percentage of individuals walking independently in the Paper population was expected 
given the significant difference in ages noted between the two populations. Arias et al also noted 
higher ages between study participants who had received respiratory care versus those who had 
not (Arias et al. 2011).  
6.3 ASSOCIATIONS BETWEEN NIFD VARIABLES 
Correlation analysis controlling for survey population was performed across most of the dataset 
to identify associations between variables. As would be expected, correlations were seen 
between increasing child age and decreased independent ambulation, use of wheelchairs and 
respiratory devices and seeing a cardiologist or pulmonologist. Regression analysis was 
performed to explore predictors for outcomes of pain and overall life satisfaction.  
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 6.3.1 Child’s Frequency of Bodily Pain or Discomfort 
Regression modeling was performed for the Paper population in regard to the child’s frequency 
of bodily pain or discomfort in the past month. This model accounted for about 44% of the 
variance in pain frequency in the Paper population. The beta value of all variables was less than 
or equal to 0.28.  
 Use of albuterol for strength, experiencing limitations due to health problems, child’s 
increased dissatisfaction with school ability, use of manual wheelchair, seeing a cardiologist and 
use of proton pump inhibitors were all associated with increases in pain frequency. Among these 
variables, the strongest predictor (beta of 0.281) was use of albuterol for strength. Use of 
albuterol, proton pump inhibitors, and seeing a cardiologist suggest respiratory, gastrointestinal 
and cardiac symptoms that could contribute to discomfort and pain.  
 Use of manual wheelchair was also a predictor for pain frequency. Use of a wheelchair 
can introduce multiple discomforts or pain making individualized adjustments, appropriate 
posturing and physical therapy critical (Bushby et al. 2010b). Wheelchair use also points to 
increased age and disease progression, which also contribute to experiences of pain.  
 Not surprisingly, increases in limitations in social and school settings due to health 
problems and in dissatisfaction with school ability were associated with increases in 
pain/discomfort frequency. This suggests that pain/discomfort can have consequences for a 
child’s social and academic life. Assessment of functioning in school and community settings 
can help identify areas where adjustments could improve discomfort or pain levels. Ideally, 
schools should also work with parents and individuals with DMD to ameliorate these issues 
(Webb 2005; Bushby et al. 2010a). 
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  Overall, these factors emphasize the importance of regular pain assessment and 
management throughout a child with DMD’s life. Suggested interventions for pain management 
from the DMD care recommendations include physical therapy, equipment enhancements, 
pharmacological approaches and, less commonly, surgical procedure (Bushby et al. 2010b).  
6.3.2 Overall Life Satisfaction 
Regression modeling was performed for the total survey population in regard to the child’s 
overall life satisfaction in the past month. This model accounted for about 53% of the variance in 
life satisfaction. The beta value of all variables was less than or equal to 0.53.  
The strongest predictor for life satisfaction was the child’s satisfaction with friendships 
(beta of 0.531), indicating the importance of social functioning and interactions. Having a 
chronic health condition can have an isolating effect on social interactions, for the family and 
particularly for children and teenagers who are forming early life relationships (Samson et al. 
2009). A study on psychosocial adjustment in boys with DMD found that while adjustment to the 
condition for the most part improves over time, relationships with peers were negatively 
correlated with age (Hendriksen et al. 2009). Pehler et al’s interviews with nine teenagers with 
DMD revealed themes of longing for less dependence on transportation to get to and more 
physical ability to participate in activities with friends (Pehler and Craft-Rosenberg 2009). In 
addition, interviewees expressed the desire to be viewed as a person rather than a disabled person 
by peers. A study of Danish men with DMD found dissatisfaction with interpersonal 
relationships, particular those of a romantic nature (Rahbek et al. 2005). Taken together, these 
studies suggest that peer relationships may be an area of difficulty throughout a person’s 
experience with DMD. Almost 8% of NIFD respondents reported that their child was involved 
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 with a support or self-help group (Table C22) and 16% said their child had seen a mental health 
therapist. Support groups can give increased opportunities for friendships and mental health 
professionals can give strategies for social interactions. Other suggestions from the DMD care 
recommendations include peer and school education on DMD; social skills training; 
modified/adapted sports, camps and youth groups; swim, horse and art therapies; service dogs 
and internet/chat rooms (Bushby et al. 2010a). 
 Child’s health other than DMD, use of ADD/ADHD medications and respondents’ worry 
for child’s behavior were also predictors of life satisfaction, pointing to other conditions and 
diagnoses as factors influencing respondents’ assessment of their child’s life satisfaction. This 
finding highlights the importance of addressing the psychosocial needs of the family and child, 
particularly in the area of behavioral concerns. Nereo et al found that maternal stress in mothers 
of boys with DMD was predicted by child’s behavioral problems, with higher stress levels in 
mothers as behavior problems increased in the children (Nereo et al. 2003). Given the potential 
impact of behavioral problems on the respondent, it is possible that NIFD respondents with 
higher worry or concern about behavior tended to assess their child’s life satisfaction as lower. 
Lack of independent walking ability was associated with decreased life satisfaction, 
which is understandable given the limitations that loss of ambulation can introduce. Impact of 
decreased abilities was a theme noted in Pehler et al’s study as teenagers with DMD expressed 
desire for the disease to slow down and longed for activities missed due to their physical 
limitations (Pehler and Craft-Rosenberg 2009). Health-related quality of life studies have also 
found physical functioning domains to be lower than controls (Bray et al. 2010; McDonald et al. 
2010; Baiardini et al. 2011). Interventions to promote mobility and independence are important 
in transitioning children and adults through decreases in physical abilities. Examples of such 
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 interventions include environmental control systems, transfer devices, customized indoor-
outdoor electric wheelchairs and electrically adjustable beds (Eagle et al. 2002; Bushby et al. 
2010b). 
6.4 COMPARISON BETWEEN NIFD AND DUCHENNECONNECT DATA 
Differences between variables examined in NIFD and DC data are discussed below. Overall, the 
data suggest that the NIFD population represents a more severely affected population (despite 
having a younger mean age of individuals with DMD) than that of DC. This would be expected 
at least in part since the NIFD Paper sub-population came from the CINRG DMD Natural 
History study, which excluded males with DMD who had milder presentation.  Additionally, 
the DC registry came out at time of increased web presence of PPMD and other advocacy 
groups; it is possible that parents and individuals with DMD became more willing to go online 
for DMD information and community involvement, especially with availability of more 
resources. However, the posting of the NIFD web-based survey did have overlap in terms of time 
with the DC profile. The enhanced marketing resources of PPMD for the DC profile compared to 
that of the NIFD could explain the significant difference in numbers recruited for the surveys. 
NIFD was also a substantially longer survey than the DC profile. NIFD Internet participants 
seemingly represent very motivated individuals who were willing and had the time to complete a 
lengthy survey. 
Taken together, the openness to individuals of any clinical course, wider marketing 
resources and significantly greater number of participants suggest that DC’s data describes a 
more representative group in terms of natural history and care experiences than that of NIFD. 
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 6.4.1 Demographic and Health Status Factors of Individuals with DMD 
The DuchenneConnect population had an older mean age (13.1 years) and wider range of ages at 
(1 to 40 years) versus NIFD’s mean age of 11.2 years (range 1 to 28 years). This difference was 
not unexpected as the NIFD Paper sub-population represented participants in the CINRG DMD 
Natural History study which included males with DMD under age 31 and the NIFD Internet sub-
population was already shown to have a lower mean age (8.8 years) than the total NIFD mean 
age. 
While both NIFD and DuchenneConnect populations had reduced representation from 
minority groups (particularly from Black/African American groups), NIFD had less racial and 
ethnic diversity than DuchenneConnect with about 91% of individuals with DMD being of 
Caucasian/non-Hispanic background versus 80% in DuchenneConnect. These numbers are 
higher than census data indicating almost 64% of the U.S. population identifies as 
Caucasian/non-Hispanic (Humes et al. 2011). The percentage of Black/African Americans in 
NIFD (2.2%) and DC (1.4%) was much lower than that of 13% in the U.S. population (Humes et 
al. 2011). This disparity in both populations emphasizes the importance of efforts to promote 
participation of individuals from minority backgrounds in both study and registry populations to 
truly depict the experiences of all families with DMD. In 2012, DuchenneConnect initiated a 
pilot project to address this issue by giving a tablet device to five US neuromuscular clinics so 
that patients and parents could register and update DC profiles while in clinic (DuchenneConnect 
2013).    
Glucocorticoid use was not significantly different between NIFD and DC populations, 
reflecting this treatment’s implementation as a standard of care for individuals with DMD. 
Ambulation ability was found to be significantly different between populations with a higher 
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 number of DC participants able to walk without help or devices. Given the higher mean age of 
participants in the DC population, it would seem that the DC population should have a higher 
proportion of non-ambulant or assistance-needing individuals. This finding could be explained, 
however, by the presence of a wider phenotypic spectrum in DC participants than that of NIFD, 
whose Paper sub-population was mostly sourced from the CINRG DMD Natural History study 
that excluded individuals who were ambulant past 13 years without glucocorticoids or ambulant 
past 16 years with glucocorticoids. It should also be noted that harmonization of walking ability 
variables between NIFD and DC also required some interpretation on the researcher’s part since 
possible response choices regarding walking ability and setting differed (eleven choices touching 
on home and outside home walking ability in NIFD versus three choices for outside home 
walking ability in DC). 
With the exception of Asperger syndrome, reported behavioral or cognitive diagnoses 
made by a doctor or other health professional were significantly lower in the DC population as 
compared to the NIFD population and the literature. This could reflect more willingness among 
more severely affected individuals and their families at the time of the NIFD survey to 
participate both in the CINRG DMD Natural History study and among individuals who chose to 
take the lengthy NIFD survey online. DC data may be more representative of the incidence of 
these conditions in the actual DMD population. There were also wording differences between the 
NIFD and DC profiles that may have influenced respondents’ selection. For instance, for the two 
highest differences in reported diagnoses between the surveys, the DC profile had “global 
developmental delay” and “speech/expressive language delay (problems explaining & describing 
things)” versus NIFD’s wording of “developmental delay” and “speech delay”. It is possible that 
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 a more specific diagnostic term precludes selection of that diagnosis in respondents who are 
unsure of a diagnosis. 
6.4.2 Insurance and Medical Expense Coverage 
Respondents for both surveys could select as many types of insurance that applied for the 
individual with DMD. A higher percentage of traditional insurance plans were selected in the 
NIFD population versus the DuchenneConnect population, which was found to be a significant 
difference. Similar percentages of Medicaid and Medicare plans were selected between the two 
populations. It is possible that more DuchenneConnect participants had traditional insurance 
plans but chose not to report them as “Prefer not to answer” was an option on this survey. 
  Significant differences were found for issues with coverage of medical expenses with 
higher percentages of the NIFD population reporting trouble with device/equipment (24% versus 
3%) and medication (11.5% versus 6.3%) expense coverage than the DC population. It is 
possible that traditional insurance plans, which the NIFD population reported a higher 
percentage of, are less likely to cover these types of expenses than other plans. A report on 
disparities in the diagnostic process of DBMD found that those with higher poverty levels had 
earlier ages of evaluation (Holtzer et al. 2011). One possibility the authors suggest is that these 
families are more likely to be on Medicaid or other public assistance programs and thus 
potentially have access to better care than those who are close to the poverty line but do not 
qualify for Medicaid. These differences in expense coverage between populations could also 
reflect better coverage over time for medications and equipment shown to be effective for DMD 
since the NIFD data were older than DC data. 
 79 
 6.4.3 Use of Therapies, Equipment and Devices 
Use of physical, occupational and speech therapies were all significantly higher in the DC 
population. This could be due to a number of reasons. From a survey perspective, NIFD asked 
about seeing each of these therapists outside of school and in the school setting in a separate 
survey section (data not analyzed) whereas DC does not distinguish between these two settings. 
Thus, the DC data could be capturing more use of these services in multiple settings than NIFD.  
NIFD respondents also reported difficulties getting these therapies covered by health insurance 
plans, which could contribute to the lower use of such services. Trouble with coverage for 
therapies was not directly queried on the DC profile. Additionally, better awareness of the 
importance of such services and possibly better coverage for them could explain higher numbers 
in the DC population. 
Use of night splints and power wheelchairs was significantly higher in the NIFD 
population and use of manual wheelchairs was significantly higher in the DC population. Usage 
of night splints was not significantly different between Paper and Internet sub-populations of 
NIFD. It is possible that, although NIFD respondents were shown to have more issues with 
coverage of expenses for devices and equipment than DC, they may have had more means to 
cover these expenses out-of-pocket. The DC profile does not record income data from 
participants so this could not be directly analyzed. The terminology used on the surveys for this 
item also differed which could have impacted selection. The NIFD survey referred to them as 
“night splints” and also provided a definition at the bottom of the page (“braces used to stretch 
the lower leg muscles at night”). Conversely, the DC profile referred to them as “AFOs (ankle-
foot-orthotics)” with no additional definition. DC participants who used these devices may not 
have selected AFOs if they did not recognize this term.  
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 Higher manual wheelchair use in the DC population and higher power wheelchair use in 
the NIFD population could also reflect a more severe clinical course in NIFD participants. In 
addition, ability to cover possible out-of-pocket expenses for power wheelchairs could have 
influenced the higher usage in the NIFD population, although the NIFD Paper sub-population 
was shown to have a higher use of power wheelchairs but yet lower incomes than the Internet 
sub-population.  
Interestingly, general use of breathing devices and use of specific devices were similar 
with no significant differences found between the NIFD and DC populations, despite the older 
average age in the DC population. This could again support that the NIFD population had a more 
severe clinical course than the DC population. It should also be noted that there was a larger non-
response rate (24%) for the DC question “Are any breathing devices used?” versus NIFD where 
a collective 6% of respondents did not respond to “Yes/No” questions for specific breathing 
devices that were combined to harmonize to DC’s breathing devices question. Despite this 
difference in response to that one item, however, use of specific breathing devices was also 
similar between the two populations.  
6.5 STUDY LIMITATIONS 
6.5.1 Survey and Analysis Methods 
Using a survey to assess families experience can be a useful tool in gathering a large amount of 
data with fewer resources. There are several limitations, however, that are introduced by using 
 81 
 this method (Bailey et al. 2010). As a cross-sectional study, NIFD cannot be used to determine 
cause/effect relationships.  
 While broader and more specific data can be captured with a detailed survey, NIFD was 
extremely long (Figure A12). Survey fatigue and lower response rate likely impacted 
participation. This seemed to be a factor particularly for the Internet population as more surveys 
were excluded from analysis from this population and, for surveys that were completed, there 
appeared to be more missing responses than the Paper population. Further, the survey sections 
examined in this study were located at the end of the Internet version versus at the beginning of 
the Paper version, thus Internet respondents may have dropped off in participation before they 
reached these sections. The Paper population may have felt more obligated to complete the NIFD 
survey since it was a part of their child’s participation in the CINRG DMD Natural History study 
versus the Internet population who likely completed the survey at home and may not have been 
aware of the survey’s length. 
 NIFD used parent or guardian-reported data, which can introduce more inaccuracy than 
direct assessment and medical data (Bailey et al. 2010). Respondents who were a part of the 
CINRG DMD Natural History study, however, did at least have confirmation of DMD diagnosis 
as a part of inclusion in the study whereas the Internet population did not have such confirmation 
and could have had an unclear or non-DMD diagnosis. Recall bias is also a limitation, especially 
for questions asking respondents to remember details on events, interventions used and visits 
made long ago, especially in older children represented in the survey.  
 There are limitations to using parent-proxy for perceptual questions about their child such 
as social functioning and quality of life (Bailey et al. 2010). Moderate to poor agreement 
between parent and patient reported physical, social and emotional functioning had been 
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 observed in DMD (Bray et al. 2010). Ideally, patient self-reports should be used but sometimes 
are not possible given the age, health status, or cognitive impairment of a child (Baiardini et al. 
2011). Most NIFD questions did not fall into this category but some did, including child’s 
limitations due to emotional or behavioral problems, satisfaction in several domains, and 
experiences of pain or discomfort. 
 Some NIFD questions may have been confusing for respondents. For example, the tense 
of a question may not have captured past use of care. Regarding visits to a provider, the NIFD 
survey asked “Does your child see” certain providers but did not ask “Has your child ever seen” 
the providers. This may be the reason why some selected “No” for seeing a provider but then 
filled in past visit info or why some selected “Yes” for seeing a provider but then gave reason 
why their child did not see that provider. Missing answers may reflect confusion or no 
appropriate response for respondent to select.  
 NIFD did not ask respondents about common surveillance methods (e.g. 
echocardiograms, forced vital capacity) that may have given a better picture of preventative care 
children were receiving without seeing a cardiologist or pulmonologist.  
 DuchenneConnect data were collected from profiles that could be updated. This means 
that some information could have been outdated for the current age and healthcare usage of 
registrants if the profile had not been recently updated. DC does not collect demographic data 
such as income and education so these factors were unable to be compared to the NIFD 
population. The DC registry requests that users submit genetic confirmation of their diagnosis 
though not all users have this confirmation nor is it required for participation. 
 Limiting analysis between NIFD and DC populations to the same age categories (e.g. 1 to 
28 years) may have been a better comparison. Another modification that could have been more 
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 insightful to assess changes over time between the two populations would be to use data from 
separate years (e.g. NIFD 2006-2009 vs. DC 2010 to 2013). Both of these modifications were 
not possible with data as received from DC but could be pursued with an updated data request to 
DC. 
  Data analysis methods used also had some limitations. Multi-collinearity between 
assigned independent variables was not analyzed in regression modeling however efforts to 
reduce these effects were made by setting unrelated variables (as determined by a correlation 
table) as independents. 
6.5.2 Study Populations 
The NIFD Paper population was a part of the CINRG DMD Natural History study which 
excluded participants who were walking past the age of 13 (without glucocorticoids) or 16 (with 
glucocorticoids), were older than age 30 years and were unwilling or unable to participate in the 
study’s protocols and visits. These criteria limit the phenotypic spectrum of the survey 
population and may select for certain characteristics of people who participate in research. For 
both Paper and Internet populations, recruiting from clinics and patient organizations can 
exclude people who are not involved with these institutions and select for participants who are 
more likely to be accessing multidisciplinary care. 
 The majority (94%) of children represented in the NIFD survey were White/Caucasian 
and about 96% were of non-Hispanic origin (Table C17). Roughly 72% of the US population is 
White and almost 84% is non-Hispanic per 2010 US Census data (Humes et al. 2011). Minority 
groups were underrepresented in the survey population since DMD affects all races and 
ethnicities. 
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  Geographical differences in care and in respondent perspectives were not explored in this 
study. Differences in region have been shown to affect utilization of and costs for care as well as 
health outcomes of individuals with chronic conditions and muscular dystrophy (Au et al. 2001; 
Shattuck and Parish 2008; Kenneson et al. 2010). About a third of NIFD respondents were from 
the Southern region of the United States while about 23 and 28% of respondents were from the 
West and Midwest, respectively (Table C17). The remainder (almost 15%) was from the 
Northeast. Thus, some regions, particularly the Northeast, may have been underrepresented 
among respondents and it is likely that families’ region of residence influenced accessibility and  
availability of services. 
6.6 FUTURE STUDIES 
There are many questions that remain to be answered related to families’ experiences with and 
utilization of healthcare in DMD. Other factors including surveillance practices (e.g. 
echocardiogram, forced vital capacity), surgeries and hospital admissions were not examined in 
this study but make up significant aspects of care for individuals with DMD. 
Regional differences in healthcare utilization were not explored in this study but 
represent another aspect affecting availability and access to multidisciplinary care. Future studies 
aimed at identifying these differences could point to regions of the US and internationally where 
adequate care is lacking. Additionally, further study of care received and factors affecting this 
care in underrepresented groups, including members of minority groups, and in those not seeking 
care at MDA clinics or other large multidisciplinary sites is warranted. This is especially true in 
light of studies showing disparities in ages at death and co-morbidities between white and black 
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 males with muscular dystrophies (Kenneson et al. 2010).  With national and international efforts 
by multiple organizations to distribute the DMD care recommendations it will be important to 
assess families’ understanding of what the recommendations entail across geographic and racial 
lines. 
Another area that future studies could address is that of availability of services and 
implementation of DMD care recommendations from the perspective of health professionals 
and/or the multidisciplinary clinic. Variations in usage of services and interventions can also 
stem from different opinions and varying agreement among the healthcare team regarding 
established care guidelines. One Canadian study of 14 pediatric neuromuscular physicians 
concluded that multidisciplinary care across the country was consistent with guidelines for DMD 
care (McMillan et al. 2010). Disparities between perceived availability and use of services 
between families and healthcare providers had been demonstrated in DMD (Madorsky et al. 
1984). In addition, numerous barriers to implementing care guidelines have been discussed from 
the provider perspective and represent an important area of study regarding the DMD care 
recommendations (Cabana et al. 1999; Littlejohns and Cluzeau 2000; Larson 2003; Mickan et al. 
2011). At the time of the NIFD survey, a Physician survey was distributed to assess the types of 
services and interventions provided to patients; 93 respondents completed surveys. This data 
could be a starting point for such a future study. Other similar investigations have been 
completed or are underway. PPMD’s DuchenneConnect site has recently opened a clinic survey 
for both families and healthcare providers to specify services offered and management practices 
utilized at clinics. In addition, the previously discussed MDA registry proposal aims to assess 
service availability and implementation of DMD care recommendations (Scully et al. 2013). In 
2012, the CDC posted a grant funding development of a plan to evaluate the delivery of 
 86 
 healthcare in accordance with DMD care recommendations (CDC 2012). These efforts will help 
identify gaps in care and lend transparency to the level of care provided across care centers, 
which overall will aid in implementation of the DMD care recommendations.  
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 7.0  CONCLUSIONS 
This present study examined healthcare utilization and perceptions from the perspective of 
families with a child with DMD by describing data from the NIFD questionnaire, which was 
taken in two formats, Paper and Internet. Analysis of the cross-sectional survey showed that at 
least half of families were receiving multidisciplinary care and felt that their healthcare was high 
quality. Mean ages at first visit for the cardiologist and pulmonologist were older than 
recommended by care guidelines and a minority of respondents whose children did not see key 
providers felt their child did not need their services. These findings highlight a need for more 
awareness and education of DMD care recommendations. Use of other sub-specialties was 
reported by about a quarter or less of respondents. Most children were currently using or had 
used glucocorticoids, a key treatment in DMD. The majority of the Paper sub-set of the NIFD 
population reported pain and discomfort in their child in varying frequencies, highlighting an 
area where individual patient assessment is warranted and broadly where more research and 
recommendations are needed. Difficulties in covering expenses were noted particularly for 
durable medical equipment and therapy. Respondents worried most about their child’s physical 
health, followed by emotional well-being and behavior. Most felt their child was not limited in 
school and social settings by these aspects and that their child was satisfied with life overall.  
Significant demographic differences noted between the NIFD sub-populations included 
higher income and education levels and lower child and parent/guardian ages in the Internet 
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 population. Further, more of the Internet population saw a neurologist or physical therapist. 
These differences highlight disparities in care that could potentially be explained by 
socioeconomic differences between families. 
Frequency of bodily pain and discomfort was associated with use of medications or 
providers related to respiratory, GI and cardiac symptoms as well as limitations due to health 
problems and satisfaction with school ability. Child’s satisfaction with life was associated with 
satisfaction with friendships, indicators of behavioral problems and walking independently. 
These associations highlight areas where healthcare providers can help families in adjusting and 
managing aspects of DMD. 
Comparison of NIFD data to a more recent dataset from DuchenneConnect, a web-based 
patient registry, showed a wider phenotypic spectrum in the latter group. DuchenneConnect 
registrants reported less problems with certain medical expenses and higher use of therapies. 
These differences point to the need to assess a large population to develop an accurate picture of 
DMD and hopefully reveal improved awareness and access to important services and 
interventions.  
This study adds to a growing effort by multiple groups to assess the services and 
interventions used by and experiences of families with DMD. Such study allows for 
identification of potential barriers to care and areas where families may need more assistance. 
These are both vital for adequate and consistent implementation of the DMD care 
recommendations across national and international care centers and for the ultimate goal of 
improving the lives of individuals and families with DMD. 
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 APPENDIX A 
SAMPLE PAGE FROM THE NIFD PAPER SURVEY 
Shown on the following page is a sample page from the Medical Care section of the 34-page 
NIFD Paper survey, demonstrating its lengthy and detailed nature, particular in this section. 
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 Figure A13: Sample page from the NIFD Paper survey 
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 APPENDIX B 
IRB EXEMPTION LETTER 
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 APPENDIX C 
DESCRIPTIVE STATISTICS ON NIFD DATA 
Data from variables not shown in the Results section but that were summarized in analysis are 
displayed below. 
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 C.1 DEMOGRAPHIC FACTORS 
Table C17: Additional demographic factors 
Demographic Characteristic  
Child’s Race (n) 
 (total n=184) 
 
Child’s Ethnicity (n) 
 (total n=185) 
 
Zip Code (n=190)  
grouped by US Census regions*  
 
 
*US Census regions (Census 2013) by state abbreviation: 
Northeast: ME, NH, VT, MA, RH, CT, NY, PA, NJ 
Midwest: WI, MI, IL, IN, OH, MO, ND, SD, NE, KS, MN, IA 
South: DE, MD, DC, VA, WV, NC, SC, GA, FL, KY, TN, MS, AL, OK, TX, AR, LA 
West: ID, MT, WY, NV, UT, CO, AZ, NM, AK, WA, OR, CA, HI 
94.0% 
3.3% 2.2% 0.5% White/Caucasian (173)
Asian/Pacific Islander
(6)
Black/African
American (4)
Native
American/Alaskan (1)
95.7% 
4.3% 
Not of
Hispanic
origin (177)
Hispanic
origin (8)
14.7% 
27.9% 
34.2% 
23.2% 
Northeast (28)
Midwest (53)
South (65)
West (44)
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 C.2 CHILD’S HEALTH STATUS 
C.2.1 Other Diagnosis or Condition 
Along with the list of prescribed diagnoses (e.g. Autism, Developmental Delay, Asperger’s 
syndrome), respondents could indicate “Yes”, “No” or “Don’t know” if their child had a 
diagnosis not listed (“Other”) with the ability to specify the diagnosis in a fill-in box. Of 135 
respondents to the “Other” category, 20.7% (28) said their child had at least one “Other” 
diagnosis; two of these said their child had two other diagnoses. The diagnoses specified by 
respondents were organized by body system and are shown below. 
Table C18: “Other” category diagnoses specified by body system 
Body System Diagnoses Specified  % (n) * 
Respiratory asthma; allergies; apnea 18.8 (6) 
Cognitive/Behavioral obsessive compulsive disorder; 
oppositional defiant disorder; 
sensory integration disorder; 
auditory memory deficit; 
processing delay; Tourette’s 
syndrome 
21.9 (7) 
Musculoskeletal Treacher-Collins syndrome; 
plagiocephaly; scoliosis; bone age 
delay; hypotonia 
15.6 (5) 
Cardiovascular heart defects; heart enlargement; 
high blood pressure 
12.5 (4) 
Gastrointestinal/ 
Genitourinary 
acid reflux; constipation; kidney 
reflux 
9.4 (3) 
Neurological epilepsy; seizures 9.4 (3) 
Other hypoglycemia; hypothyroidism; 
recurrent ear infections; glycerol 
kinase deficiency 
12.5 (4) 
* Of n=32 total diagnoses specified by respondents 
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 C.3 MEDICAL CARE 
C.3.1 Pediatrician, Distance and Location of Healthcare Providers 
Table C19: Details on healthcare providers 
Question Result: % (n) Total 
question 
response 
Pediatrician or other child health 
care provider (outside of the 
MDA clinic) seen for check-ups 
every year and for routine health 
care (Y/N) 
Yes: 93.1 (176) 
No: 6.9 (13) 
189 
One-way, single trip distance to 
see health care providers 
involved in child's health care 
 
Under 10 miles: 14.8 (27) 
10 to 50 miles: 52.2 (95) 
> 50 miles: 33 (60) 
182 
Location of majority of child's 
health care providers 
MDA clinic: 46.3 (76) 
Private provider: 31.1 (51) 
Hospital: 17.1 (28) 
Other: 4.9 (8)           
Community free clinic: 0 (0) 
164 
 
C.3.2 Write-in Comments on Quality of Child’s Healthcare 
Forty-four (23% of the total survey population) gave write-in comments about the quality of their 
child’s healthcare since his diagnosis with DMD. Several themes emerged from among 
respondents’ comment including praise for care, dissatisfaction with clinic logistics and/or 
doctors, and difficulty getting access to certain therapies.  
Overall, 15 responses included positive comments on healthcare, using words like 
“excellent”, “great”, “high-quality” and “wonderful”. One respondent observed improvement of 
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 care since diagnosis, another mentioned the lack of standards of care and a third expressed 
disappointment with the progress and speed of research.  
Comments also addressed issues of logistics in terms of care for the child with DMD. 
Five respondents noted long distances to care providers and seven mentioned that they switched 
their care location or moved to access better care. Many of these respondents were traveling 
across the United States to receive specialized care. Respondents expressed frustration at 
changes in doctors at clinics, billing practices and difficulties communicating with staff 
members. Three respondents mentioned dissatisfaction with long wait times for referrals, 
approvals, equipment and test results.  
There were multiple comments on dissatisfaction with doctors. Four respondents cited 
disagreement on care or opinions between clinic doctors or across aid programs. Several 
respondents expressed dissatisfaction at the willingness of doctors to try treatments and be 
proactive in their approach (e.g. “I push for more when the doctors feel they are finished for the 
time being”). Respondents commented on providers lacking up-to-date information on DMD 
with one respondent saying that the “quality of healthcare varied widely depending on providers 
previous experience with DMD and willingness to learn and obtain current information about 
DMD”. 
Some respondents felt that they needed more of certain types of care (e.g. physical 
therapy, pool therapy, medical equipment) but mentioned barriers to getting them. Six 
respondents expressed that they had to make demands and/or spend great amounts of time 
learning about DMD in order to get good care. For example, one respondent said, “The doctor is 
not forth coming [with] information regarding DMD trials or things going on. We have had to 
find items of interest relating to DMD and approach the doctor with them”. 
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 C.3.3 Healthcare Providers & Services 
Additional variables regarding interactions with healthcare providers are shown in the 
tables below. 
Table C20: Frequency of child's visits to doctors and other health professionals 
 
 
Table C21: Reasons why child does not see selected providers 
Doctor or Health 
Professional* 
Total 
response 
None 
available 
% (n) 
Too 
expensive 
% (n) 
Concern 
about 
medical 
insurance 
% (n) 
Child 
does not 
need this 
service % 
(n) 
Other % 
(n) 
Nutritionist 118 7.6 (9) 1.7 (2) 3.4 (4) 72.9 (86) 14.4 (17) 
Physiatrist 123 1.6 (2) 2.4 (3) 0.8 (1) 81.3 (100) 13.8 (17) 
Occupational a 118 8.5 (10) 7.6 (9) 6.8 (8) 55.9 (66) 21.2 (25) 
Social worker 122 7.4 (9) 0 (0) 0.8 (1) 85.2 (104) 6.6 (8) 
Gastroenterologist 135 3 (4) 0 (0) 0 (0) 89.6 (121) 7.4 (10) 
Mental Health  133 3.8 (5) 0.8 (1) 0 (0) 83.5 (111) 12 (16) 
Speech a 143 2.1 (3) 2.1 (3) 1.4 (2) 83.9 (120) 10.5 (15) 
* “Religious reason” was an additional answer option but no respondent selected this answer for any provider type 
a therapist seen outside of school 
Doctor 
Total 
response 
Only one 
time % 
(n) 
Every 3 
months % 
(n) 
Every 6 
months % 
(n) 
Every 
year % 
(n) 
As needed 
% (n) 
Neurologist  147 6.1 (9) 24.5 (36) 52.4 (77) 8.2 (12) 8.8 (13) 
Cardiologist  123 8.9 (11) 2.4 (3) 19.5 (24) 58.5 (72) 10.6 (13) 
Pulmonologist 92 5.4 (5) 5.4 (5) 37 (34) 34.8 (32) 17.4 (16) 
Physical therapist a 88 8 (7) 36.4 (32) 19.3 (17) 15.9(14) 3.4 (3) 
Nutritionist 47 23.4 (11) 0 (0) 0 (0) 27.7(13) 19.1(9) 
Physiatrist 47 10.6 (5) 27.7 (13) 27.7 (13) 4.3 (2) 29.8 (14) 
Occupational a 47 6.4 (3) 27.7 (13) 14.9 (7) 14.9 (7) 4.3 (2) 
Social worker 38 5.3 (2) 0 (0) 15.8 (6) 23.7 (9) 13.2 (5) 
Gastroenterologist 29 27.6 (8) 13.8 (4) 6.9 (2) 13.8 (4) 37.9 (11) 
Mental Health 28 3.6 (1) 10.7 (3) 28.6 (8) 7.1 (2) 7.1 (2) 
Speech a 14 14.3 (2) 50 (7) 7.1 (1) 14.3 (2) 0 (0) 
a therapist seen outside of school; mo. = month(s); #/week or mo. = number of times per week or month 
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 Table C22: Participation of child and/or respondent in support groups, mental health therapy                         
and clinical trials 
 
Service* 
Count 
(Yes) 
Count 
(No) 
Total 
Response 
Percentage 
(Yes/Total 
Response) 
Support/self help groupsa (Child)  14 165 179 7.8 
Support/self help groupsa  (Respondent) 54 129 183 29.5 
Mental Health Therapist (Respondent) 35 144 179 19.6 
Clinical trial to treat DMD (Child) 62 119 181 34.3 
* Respondents were asked “Does your child/Do you participate in or seek help from the following?” 
(Yes/No) 
a  to cope with problems related to DMD 
 
 
Table C23: Frequency of visits to support groups, mental health therapy and clinical trials for child and/or 
respondent 
Service 
Total 
response 
Only 
once % 
(n) 
1-3/week 
% (n) 
1-2/mo. 
% (n) 
Every 6 
mo. % 
(n) 
Yearly 
% (n) 
As 
needed 
% (n) 
Supporta (Child) 11 18.2 (2) 0 (0) 9.1 (1) 27.3 (3) 9.1 (1) 36.4 (4) 
Supporta  (Res) 50 10 (5) 12 (6) 32 (16) 4 (2) 10 (5) 32 (16) 
Mental Healthb (Res) 33 6.1 (2) 27.3 (9) 9.1 (3) 6.1 (2) 3 (1) 48.5(16) 
Clinical trial (Child) 53 15.1 (8) 0 (0) 3.8 (2) 34 (18) 11.3 (6) 35.8(19) 
a support or self help groups to cope with problems related to DMD 
b mental health therapist 
Res= respondent; mo. = month(s); #/week or mo. = number of times per week or month 
 
 
Table C24: Reasons why child and/or respondent does not participate in support groups, mental health 
therapy and clinical trials 
Service 
Total 
response a 
None 
available 
% (n) 
Too 
expensive 
% (n) 
Concern 
about 
medical 
insurance 
% (n) 
Child/Res 
does not 
need this 
service % 
(n) 
Other % 
(n) 
Support b (Child) 150 26.7 (40) 0 (0) 0.7 (1) 40 (60) 32.7 (49) 
Support b  (Res) 118 26.3 (31) 0 (0) 1.7 (2) 31.4 (37) 40.7 (48) 
Mental Healthc (Res) 128 2.3 (3) 4.7 (6) 3.1 (4) 68 (87) 21.9 (28) 
Clinical trial (Child) 104 68.3 (71) 0 (0) 0 (0) 11.5 (12) 20.2 (21) 
a “Religious reason” was an additional answer option but no respondent selected this answer for any service type 
b support or self help groups to cope with problems related to DMD 
c mental health therapist 
Res = respondent 
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 C.3.4 Medications 
Table C25: Medications to help increase or maintain strength: glucocorticoids 
Medication  
Count 
(Yes)a 
Total 
responses Percentage 
If yes, still use 
it? b % (n)  
Total 
responses 
Prednisone 98 175 56 63.6 (63) 99 
Prednisolone 13 171 7.6 56.3 (9) 16 
Deflazacort 37 172 21.5 80 (32) 40 
a Response to: “Has your child used the following? (Yes/No)” 
b Response to: “If yes [child uses medication], does he still use it?” 
 
 
 
Table C26: Reasons why glucocorticoids were not used among those who have used them previously 
Medication  
Total 
Response a 
No one 
prescribed 
it  % (n) 
Does not 
need it % 
(n) 
Too 
expensive 
% (n) 
Not 
available 
% (n) 
Too many 
side 
effects % 
(n) 
Would 
not take it 
% (n) 
Prednisone 26 0 (0) 26.9 (7) 0 (0) 0 (0) 73.1 (19) 3.8 (1) 
Prednisolone 4 25 (1) 0 (0) 0 (0) 0 (0) 75 (3) 0 (0) 
Deflazacort 7 0 (0) 14.3 (1) 28.6 (2) 28.6 (2) 28.6 (2) 0 (0) 
a Respondents who answered Yes to “Has your child used the following” and selected a reason for why their child 
was not using glucocorticoids. 
 
Table C27: Medications to help the heart 
Medication 
Count 
(Yes)a 
Total 
responses Percentage 
ACE inhibitors 22 179 12.3 
Beta Blockers 14 177 7.9 
Digoxin 11 176 6.3 
Diuretics  7 176 4.0 
Anti-Arrhythmic 3 172 1.7 
a Response to: “Has your child used the following? (Yes/No)” 
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 C.3.5 Durable Medical Equipment 
Table C28: Use of bracing 
Equipment 
Count 
(Yes) a 
Total 
Response 
Percentage 
Short leg braces 46 180 25.6 
Long leg braces 18 179 10.1 
a Response to: “Has your child used the following? (Yes/No)” 
 
 
Table C29: Reasons why child had not used splints and bracing 
Equipment  
Total 
Response a 
Never 
suggested  
% (n) 
No need % 
(n) 
He would 
refuse % 
(n) 
Not 
available % 
(n) 
Other % 
(n) 
  Night splints 65 29.2 (19) 40.0 (26) 20.0 (13) 1.5(1) 9.2 (6) 
Short leg braces 121 48.8 (59) 43.0 (52) 5.0 (6) 0 (0) 3.3 (4) 
Long leg braces 148 44.6 (66) 48.6 (72) 4.1 (6) 0 (0) 2.7 (4) 
a “Cannot afford” was an additional answer option but no respondent selected this answer for any equipment type 
 
C.3.6 Pulmonary Devices 
Table C30: Use of pulmonary devices 
Pulmonary Devices 
Count 
(Yes) a 
Total 
responses Percentage 
Current mean 
age years  
(SD, range) 
Emerson Cough Assist 21 179 11.7 20 (±5;9-28) 
Other Lung Clearance Devices b 24 180 13.3 17 (±5;4-28) 
Tracheotomy 3 179 1.7 23 (±3;21-26) 
Other Assisted Ventilation Devices c 25 179 14 20 (±4;12-28) 
Breathing Exercises 23 176 13.1 16 (±5;3 to 26) 
SD: standard deviation 
a Response to: “Has your child used the following? (Yes/No)” 
b Respondents selecting one or more of: Vortran percussive nebulizer, Intrapulmonary 
percussive ventilation (IPV), Chest percussion, TheraVest/Pulmonary Vest 
c Respondents selecting one of more of: Bi-PAP, C-PAP, Mouthpiece/Sip’n puff 
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 C.3.7 Complementary and/or Alternative Medicine & Supplements 
Several questions pertaining to complementary and alternative medicine were asked on the NIFD 
survey. Of 180 who responded, about 18% (n=32) said they had visited an alternative medicine 
practitioner to treat their child with DMD. About 42% (n=81) of all respondents selected one or 
more complementary or alternative medicine approach that their child tried. The 152 selections 
made among the approach types are shown in Figure C14.  
About 49% (n=94) of all survey respondents selected one or more supplement type that 
their child used. The 276 selections made among the supplement types are shown in Table C31. 
 
 
Figure C14: Complementary and/or alternative medicine approaches 
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 Table C31: Use of supplements 
 Types of Supplements 
Responses 
N Percent 
Calcium 78 28.3% 
Coenzyme Q10 45 16.3% 
Creatinine 23 8.3% 
Vitamin E 22 8.0% 
Glutamine 17 6.2% 
Magnesium 13 4.7% 
Omega-3 Fatty Acids 13 4.7% 
Vitamin B12 12 4.3% 
Carnitine (L-Carnitine) 10 3.6% 
L-Arginine 10 3.6% 
Vitamin B6 10 3.6% 
Selenium 8 2.9% 
Potassium 6 2.2% 
Juven 4 1.4% 
Omega 6 Fatty Acids 4 1.4% 
Cysteine 1 0.4% 
Total 276 100.0% 
C.3.8 Surgeries 
Respondents were able to specify what age and type of surgery or surgeries their child had. 23% 
(n=44) of respondents reported that their child had one or more surgeries.  
Table C32: Surgeries by type and age 
Surgery Type % of total 
NIFD 
population (n) 
Mean age, 
years (±SD) 
Age range, 
years 
Tendon release (ankle)  14.1 (27) 10.3±2.6 3 to 15 
Spinal fusion 13.1 (25) 14.5±1.7 10 to 17 
Hip surgery  2.1 (4) 13.75±4.9 9 to 20 
Tracheotomy 1.6 (3) 22.7±3.1 20 to 26 
Knee 1.0 (2) 12±4.2 9, 15 
Other 20 (38) 7.7±7.2 <1 to 20 
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